Junya Fujimoto, M.D., Ph.D.

Peer-Reviewed Articles

1. Akhave N, Zhang J, Bayley E, Frank M, Chiou SH, Behrens C, Chen R, Hue X, Parra ER, Lee WC, Swisher S, Solis L, Weissferdt A, Moran C, Kalhor N, Zhang J, Scheet P, Vaporciyan AA, Sepesi B, Gibbons DL, Heymach JV, Lee JJ, Wistuba II, Futreal PA, Zhang J, Fujimoto J, Reuben A. Immunogenomic profiling of lung adenocarcinoma reveals poorly differentiated tumors are associated with an immunogenic tumor microenvironment. Lung Cancer 172:19-28, 2022.
2. Hao D, Han G, Sinjab A, Bolanos LIG, Segura RL, Serrano A, Hernandez SD, Dai E, Cao X, Hu J, Dang M, Wang R, Chu Y, Song X, Zhang J, Parra ER, Wargo J, Swisher S, Cascone T, Sepesi B, Futreal AP, Li M, Dubinett S, Fujimoto F, Solis Soto LM, Wistuba II, Stevenson CS, Spira AE, Shalapour S, Kadara H, Wang L. The Single-Cell Immunogenomic Landscape of B and Plasma Cells in Early-Stage Lung Adenocarcinoma. Cancer Discov CD-21-1658, 2022. e-Pub 2022. PMID: 36098652.
3. Zhang B, Stewart CA, Wang Q, Cardnell RJ, Rocha P, Fujimoto J, Solis Soto LM, Wang R, Novegil V, Ansell P, He L, Fernandez L, Jendrisak A, Gilbertson C, Schonhoft JD, Byun J, Jones J, Anderson AKL, Aparicio A, Tran H, Negrao MV, Zhang J, Wang WL, Wistuba II, Wang J, Wenstrup R, Byers LA, Gay CM. Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancer. Br J Cancer 127(3):569-576, 2022. e-Pub 2022. PMID: 35440668.
4. Hassane M, Rahal Z, Karaoghlanian N, Zhang J, Sinjab A, Wong JW, Lu W, Scheet P, Lee JJ, Raso MG, Solis LM, Fujimoto J, Chami H, Shihadeh AL, Kadara H. Chronic Exposure to Waterpipe Smoke Elicits Immunomodulatory and Carcinogenic Effects in the Lung. Cancer Prev Res (Phila) 15(7):423-434, 2022. PMID: 35468191.
5. Schmidt ST, Akhave N, Knightly RE, Reuben A, Vokes N, Zhang J, Li J, Fujimoto J, Byers LA, Sanchez-Espiridion B, Diao L, Federico L, Forget M-A, McGrail DJ, Weissferdt A, Lin S-Y, Lee Y, Suzuki E, Kovacs JJ, Behrens C, Wistuba II, Futreal A, Vaporciyan A, Sepesi B, Heymach J, Bernatchez C, Haymaker C, Cascone T, Zhang J, Bristow CA, Heffernan TP, Negrao MV, Gibbons DL, the ICON Team. Shared Nearest Neighbors Approach and Interactive Browser for Network Analysis of a Comprehensive Non–Small-Cell Lung Cancer Data Set. JCO Clin. Cancer Inform:Article Number: e2200040, 2022. PMID: 35944232.
6. Rocha P, Zhang J, Laza-Briviesca R, Cruz-Bermúdez A, Bota-Rabassedas N, Sanchez-Espiridon B, Yoshimura K, Behrens C, Lu W, Tang X, Pataer A, Parra ER, Haymaker C, Fujimoto J, Swisher SG, Heymach JV, Gibbons DL, Lee JJ, Sepesi B, Cascone T, Solis LM, Provencio M, Wistuba II, Kadara H. Distinct Immune Gene Programs Associated with Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable NSCLC. Clin Cancer Res 28(11):2461-2473, 2022. PMID: 35394499.
7. Chen R, Li J, Fujimoto J, Hong L, Hu X, Quek K, Tang M, Mitra A, Behrens C, Chow CW, Jiang P, Little LD, Gumbs C, Song X, Zhang J, Tan D, Heymach JV, Wistuba I, Futreal PA, Gibbons DL, Byers LA, Zhang J, Reuben A. Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma. J Exp Clin Cancer Res 41(1):Article number: 172, 2022. PMID: 35546239.
8. Tanaka I, Dayde D, Tai MC, Mori H, Solis LM, Tripathi SC, Fahrmann JF, Unver N, Parhy G, Jain R, Parra ER, Murakami Y, Aguilar-Bonavides C, Mino B, Celiktas M, Dhillon D, Casabar JP, Nakatochi M, Stingo F, Baladandayuthapani V, Wang H, Katayama H, Dennison JB, Lorenzi PL, Do KA, Fujimoto J, Behrens C, Ostrin EJ, Rodriguez-Canales J, Hase T, Fukui T, Kajino T, Kato S, Yatabe Y, Hosoda W, Kawaguchi K, Yokoi K, Chen-Yoshikawa TF, Hasegawa Y, Gazdar AF, Wistuba II, Hanash S, Taguchi A. SRGN-Triggered Aggressive and Immunosuppressive Phenotype in a Subset of TTF-1-Negative Lung Adenocarcinomas. J Natl Cancer Inst 114(2):290-301, 2022. e-Pub 2021. PMID: 34524427.
9. Shah P, Forget M, Frank ML, Federico L, Jiang P, Khairullah R, Wistuba II, Chow C, Long Y, Fujimoto J, Lin S, Maitra A, Negrao MV, Mitchell KG, Weissferdt A, Vaporciyan AA, Cascone T, Roth J, Zhang J, Sepesi B, Gibbons DL, Heymach JV, Haymaker C, McGrail DJ, Reuben A, Bernatchez C. Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes. J Immunother Cancer:Article number: e003082, 2022. PMID: 35110355.
10. Tang M, Abbas HA, Negrao MV, Ramineni M, Hu X, Hubert SM, Fujimoto J, Reuben A, Varghese S, Zhang J, Li J, Chow CW, Mao X, Song X, Lee WC, Wu J, Little L, Gumbs C, Behrens C, Moran C, Weissferdt A, Lee JJ, Sepesi B, Swisher S, Cheng C, Kurie J, Gibbons D, Heymach JV, Wistuba II, Futreal PA, Kalhor N, Zhang J. The histologic phenotype of lung cancers is associated with transcriptomic features rather than genomic characteristics. Nat Commun 12(1):Article number: 7081, 2021. PMID: 34873156.
11. Zhang B, Ramkumar K, Cardnell RJ, Gay CM, Stewart CA, Wang WL, Fujimoto J, Wistuba II, Byers LA. A wake-up call for cancer DNA damage: the role of Schlafen 11 (SLFN11) across multiple cancers. Br J Cancer 125(10):1333-1340, 2021. PMID: 34294893.
12. Chen M, Chen R, Jin Y, Li J, Hu X, Zhang J, Fujimoto J, Hubert SM, Gay CM, Zhu B, Tian Y, McGranahan N, Lee WC, George J, Hu X, Chen Y, Wu M, Behrens C, Chow CW, Pham HHN, Fukuoka J, Wu J, Parra ER, Little LD, Gumbs C, Song X, Wu CJ, Diao L, Wang Q, Cardnell R, Zhang J, Wang J, Le X, Gibbons DL, Heymach JV, Jack Lee J, William WN Jr, Cheng C, Glisson B, Wistuba I, Andrew Futreal P, Thomas RK, Reuben A, Byers LA, Zhang J. Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer. Nat Commun 12(1):Article number: 6655, 2021. PMID: 34789716.
13. Sinjab A, Han G, Treekitkarnmongkol W, Hara K, Brennan PM, Dang M, Hao D, Wang R, Dai E, Dejima H, Zhang J, Bogatenkova E, Sanchez-Espiridion B, Chang K, Little DR, Bazzi S, Tran LM, Krysan K, Behrens C, Duose DY, Parra ER, Raso MG, Solis LM, Fukuoka J, Zhang J, Sepesi B, Cascone T, Byers LA, Gibbons DL, Chen J, Moghaddam SJ, Ostrin EJ, Rosen D, Heymach JV, Scheet P, Dubinett SM, Fujimoto J, Wistuba II, Stevenson CS, Spira A, Wang L, Kadara H. Resolving the spatial and cellular architecture of lung adenocarcinoma by multiregion single-cell sequencing. Cancer Discov 11(10):2506-2523, 2021. PMID: 33972311.
14. Byers LA, Bentsion D, Gans S, Penkov K, Son C, Sibille A, Owonikoko TK, Groen HJ, Gay CM, Fujimoto J, de Groot P, Dunbar M, Kang K, He L, Sehgal V, Glasgow J, Bach BA, Ellis PM. Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naïve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study. Clin Cancer Res 27(14):3884-3895, 2021. PMID: 33947690.
15. Dejima H, Hu X, Chen R, Zhang J, Fujimoto J, Parra ER, Haymaker C, Hubert SM, Duose D, Solis LM, Su D, Fukuoka J, Tabata K, Pham HHN, Mcgranahan N, Zhang B, Ye J, Ying L, Little L, Gumbs C, Chow CW, Estecio MR, Godoy MCB, Antonoff MB, Sepesi B, Pass HI, Behrens C, Zhang J, Vaporciyan AA, Heymach JV, Scheet P, Lee JJ, Wu J, Futreal PA, Reuben A, Kadara H, Wistuba II, Zhang J. Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features. Nat Commun 12(1):Article number: 2722, 2021. PMID: 33976164.
16. Gay CM, Stewart CA, Park EM, Diao L, Groves SM, Heeke S, Nabet BY, Fujimoto J, Solis LM, Lu W, Xi Y, Cardnell RJ, Wang Q, Fabbri G, Cargill KR, Vokes NI, Ramkumar K, Zhang B, Della Corte CM, Robson P, Swisher SG, Roth JA, Glisson BS, Shames DS, Wistuba II, Wang J, Quaranta V, Minna J, Heymach JV, Byers LA. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell 39(3):346-360, 2021. PMID: 33482121.
17. Cascone T, William WN, Weissferdt A, Leung CH, Lin HY, Pataer A, Godoy MCB, Carter BW, Federico L, Reuben A, Khan MAW, Dejima H, Francisco-Cruz A, Parra ER, Solis LM, Fujimoto J, Tran HT, Kalhor N, Fossella FV, Mott FE, Tsao AS, Blumenschein G, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Roth JA, Antonoff MB, Kadara H, Haymaker C, Bernatchez C, Ajami NJ, Jenq RR, Sharma P, Allison JP, Futreal A, Wargo JA, Wistuba II, Swisher SG, Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Sepesi B. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med 27(3):504-514, 2021. PMID: 33603241.
18. Han G, Sinjab A, Hara K, Treekitkarnmongkol W, Brennan P, Chang K, Bogatenkova E, Sanchez-Espiridion B, Behrens C, Solis LM, Gao B, Girard L, Zhang J, Sepesi B, Cascone T, Byers LA, Gibbons DL, Chen J, Moghaddam SJ, Ostrin EJ, Scheet P, Fujimoto J, Shay J, Heymach JV, Minna JD, Dubinett S, Wistuba II, Stevenson CS, Spira AE, Wang L, Kadara H. Single-Cell Expression Landscape of SARS-CoV-2 Receptor ACE2 and Host Proteases in Normal and Malignant Lung Tissues from Pulmonary Adenocarcinoma Patients. Cancers (Basel) 13(6):1250, 2021. PMID: 33809063.
19. Cai L, Liu H, Huang F, Fujimoto J, Girard L, Chen J, Li Y, Zhang YA, Deb D, Stastny V, Pozo K, Kuo CS, Jia G, Yang C, Zou W, Alomar A, Huffman K, Papari-Zareei M, Yang L, Drapkin B, Akbay EA, Shames DS, Wistuba II, Wang T, Johnson JE, Xiao G, DeBerardinis RJ, Minna JD, Xie Y, Gazdar AF. Cell-autonomous immune gene expression is repressed in pulmonary neuroendocrine cells and small cell lung cancer. Commun Biol 9(1):314, 2021. PMID: 33750914.
20. Treekitkarnmongkol W, Hassane M, Sinjab A, Chang K, Hara K, Rahal Z, Zhang J, Lu W, Sivakumar S, McDowell TL, Kantrowitz J, Zhou J, Lang W, Xu L, Ochieng JK, Nunomura-Nakamura S, Deng S, Behrens C, Raso MG, Fukuoka J, Reuben A, Ostrin EJ, Parra E, Solis LM, Spira AE, McAllister F, Cascone T, Wistuba II, Moghaddam SJ, Scheet PA, Fujimoto J, Kadara H.. Augmented Lipocalin-2 is Associated with COPD and Counteracts Lung Adenocarcinoma Development. Am J Respir Crit Care Med 203(1):90-101, 2021. PMID: 32730093.
21. Gaudreau PO, Negrao MV, Mitchell KG, Reuben A, Corsini EM, Li J, Karpinets T, Wang Q, Diao L, Wang J, Federico L, Parra-Cuentas ER, Khairullah R, Behrens C, Correa AM, Gomez D, Little L, Gumbs C, Kadara H, Fujimoto J, McGrail DJ, Vaporciyan AA, Swisher SG, Walsh G, Antonoff MB, Weissferdt A, Tran H, Roarty E, Haymaker C, Bernatchez C, Zhang J, Futreal PA, Wistuba II, Cascone T, Heymach JV, Sepesi B, Zhang J, Gibbons DL. Neoadjuvant Chemotherapy Increases Cytotoxic T cell, Tissue Resident Memory T cell and B Cell Infiltration in Resectable Non-Small Cell Lung Cancer. J Thorac Oncol 16(1):127-139, 2021. PMID: 33096269.
22. Hu X, Estecio MR, Chen R, Reuben A, Wang L, Fujimoto J, Carrot-Zhang J, McGranahan N, Ying L, Fukuoka J, Chow CW, Pham HN, Godoy MCB, Carter BW, Behrens C, Zhang J, Antonoff MB, Sepesi B, Lu Y, Pass HI, Kadara H, Scheet P, Vaporciyan AA, Heymach JV, Wistuba II, Lee JJ, Futreal PA, Su D, Issa JP, Zhang J. Evolution of DNA methylome from precancerous lesions to invasive lung adenocarcinomas. Nat Commun 12(1):Article number: 687, 2021. PMID: 33514726.
23. Zaleski M, Kalhor N, Fujimoto J, Wistuba I, Moran CA. Sarcomatoid Mesothelioma: A CDKN2A molecular analysis of 53 cases with immunohistochemical correlation with BAP1. Pathol Res Pract 216(12):Article number: 153267, 2020. PMID: 33176261.
24. Lee WC, Reuben A, Hu X, McGranahan N, Chen R, Jalali A, Negrao MV, Hubert SM, Tang C, Wu CC, Lucas AS, Roh W, Suda K, Kim J, Tan AC, Peng DH, Lu W, Tang X, Chow CW, Fujimoto J, Behrens C, Kalhor N, Fukumura K, Coyle M, Thornton R, Gumbs C, Li J, Wu CJ, Little L, Roarty E, Song X, Lee JJ, Sulman EP, Rao G, Swisher S, Diao L, Wang J, Heymach JV, Huse JT, Scheet P, Wistuba II, Gibbons DL, Futreal PA, Zhang J, Gomez D, Zhang J. Multiomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity. Genome Biol 21(1):Article number: 271, 2020. PMID: 33148332.
25. Boyle TA, Khalil FK, Mino-Kenudson M, Sica GL, Moreira AL, Sholl LM, Knight MZ, Zhang L, Saller J, Varella-Garcia M, Berry LD, Chen H, Ellison KE, Rivard CJ, Kugler K, Wistuba II, Fujimoto J, Kwiatkowski DJ, Bunn PA, Kris MG, Haura EB, Hirsch FR; Lung Cancer Mutation Consortium (LCMC) Pathologist Panel Group. Round Robin Evaluation of MET Protein Expression in Lung Adenocarcinomas Improves Interobserver Concordance Pathologist Evaluation of MET Protein Expression. Appl Immunohistochem Mol Morphol 28(9):669-677, 2020. PMID: 31876606.
26. Mitchell KG, Parra ER, Zhang J, Nelson DB, Corsini EM, Villalobos P, Moran CA, Skoulidis F, Wistuba II, Fujimoto J, Roth JA, Antonoff MB, MD Anderson Lung Cancer Immune Microenvironment Working Group. LKB1/STK11 expression in lung adenocarcinoma and associations with patterns of recurrence. Ann Thorac Surg 110(4):1131-1138, 2020. PMID: 32442617.
27. Thomas A, Mian I, Tlemsani C, Pongor L, Takahashi N, Maignan K, Snider J, Li G, Frampton G, Ali S, Kim S, Nichols S, Rajapakse V, Guha U, Sharon E, Fujimoto J, Moran C, Wistuba I, Wei J, Khan J, Szabo E, Torres A, Carson K. Clinical and Genomic Characteristics of Small Cell Lung Cancer in Never-Smokers: Results From a Retrospective Multicenetr Cohort Study. Chest 158(4):1723-1733, 2020. PMID: 32464188.
28. Chen R, Lee WC, Fujimoto J, Li J, Hu X, Mehran R, Rice D, Swisher SG, Sepesi B, Tran HT, Chow CW, Little LD, Gumbs C, Haymaker C, Heymach JV, Wistuba II, Lee JJ, Futreal PA, Zhang J, Reuben A, Tsao AS, Zhang J.. Evolution of Genomic and T-cell Repertoire Heterogeneity of Malignant Pleural Mesothelioma Under Dasatinib Treatment. Clin Cancer Res 26(20):5477-5486, 2020. PMID: 32816946.
29. Carroll MR, Ramalingam P, Salvo G, Fujimoto J, Solis Soto LM, Phoolcharoen N, Hillman RT, Cardnell R, Byers L, Frumovitz M.. Evaluation of PARP and PDL-1 as potential therapeutic targets for women with high-grade neuroendocrine carcinomas of the cervix. Int J Gynecol Cancer 30(9):1303-1307, 2020. PMID: 32727929.
30. Ci B, Yang DM, Cai L, Yang L, Girard L, Fujimoto J, Wistuba II, Xie Y, Minna J, Travis W, Xiao G. Molecular differences across invasive lung adenocarcinoma morphological subgroups. Transl Lung Cancer Res 9(4), 2020. PMID: 32953482.
31. Mitchell KG, Amini B, Wang Y, Carter BW, Godoy MCB, Parra ER, Behrens C, Villalobos P, Reuben A, Lee JJ, Weissferdt A, Moran CA, Fujimoto J, Sepesi B, Walsh GL, Vaporciyan AA, Hofstetter WL, William WN Jr, Gibbons DL, Wang J, Hwu P, Swisher SG, Piwnica-Worms D, Kadara H, Wistuba II, Heymach JV, Peng W, Cascone T. (18)F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancer. Cancer Immunol Immunother 69(8):1519-1534, 2020. e-Pub 2020. PMID: 32300858.
32. Hillman RT, Cardnell R, Fujimoto J, Lee WC, Zhang J, Byers LA, Ramalingam P, Leitao M, Swisher E, Futreal PA, Frumovitz M. Comparative genomics of high grade neuroendocrine carcinoma of the cervix. PLoS One 15(6):e0234505, 2020. PMID: 32544169.
33. Wang S, Rong R, Yang DM, Fujimoto J, Yan S, Cai L, Yang L, Luo D, Behrens C Parra ER, Yao B, Xu L, Wang T, Zhan X, Wistuba II, Minna JXie Y, Xiao G. Computational staining of pathology images to study tumor microenvironment in lung cancer. Cancer Res 80(10):2056-2066, 2020. e-Pub 2020. PMID: 31915129.
34. Della Corte CM, Sen T, Gay CM, Ramkumar K, Diao L, Cardnell RJ, Rodriguez BL, Stewart CA, Papadimitrakopoulou VA, Gibson L, Fradette JJ, Wang Q, Fan Y, Peng DH, Negrao MV, Witsuba II, Fujimoto J, Solis Soto LM, Behrens C, Skoulidis F, Heymach JV, Wang J, Gibbons DL, Byers LA. STING pathway expression identifies non-small cell lung cancers with an immune-responsive phenotype. J Thorac Oncol 15(5):777-791, 2020. e-Pub 2020. PMID: 32068166.
35. Corsini EM, Wang J, Wu C-C, Fujimoto J, Negrao MV, Chen R, MD, Quek K, Mitchell KG, Chow C-W, Little L, Gumbs C, Song X, Behrens C, Correa AM, Antonoff MB, Swisher SG, Heymach JV, Zhang J, Wistuba II, Futreal PA, Sepesi B, Zhang J. Genomic Assessment Distinguishes Intrapulmonary Metastases From Synchronous Primary Lung Cancers. J Thorac Dis 12(5):1952-1959, 2020. PMID: 32642098.
36. Nelson DB, Mitchell KG, Wang J, Fujimoto J, Godoy M, Behrens C, Zheng X, Zhang J, Sepesi B, Vaporciyan AA, Hofstetter WL, Mehran RJ, Rice DC, Walsh GL, Swisher SG, Moran CA, Kalhor N, Weissferdt A, Wistuba II, Roth JA, Antonoff MB. Immune Regulatory Markers of Lepidic-Pattern Adenocarcinomas Presenting as Ground Glass Opacities. J Thorac Dis 12(3):329-337, 2020. PMID: 32274099.
37. Stewart CA, Gay CM, Xi Y, Sivajothi S, Sivakamasundari V, Fujimoto J, Bolisetty M, Hartsfield PM, Balasubramaniyan V, Chalishazar MD, Moran CA, Kalhor N, Stewart J, Tran H, Swisher SG, Roth JA, Zhang J, de Groot J, Glisson B, Oliver TG, Heymach JV, Wistuba II, Robson P, Wang J, Byers LA. Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small cell lung cancer. Nat Cancer(1):423-426, 2020. PMID: 33521652.
38. Reuben A, Zhang J, Chiou SH, Gittelman RM, Li J, Lee WC, Fujimoto J, Behrens C, Liu X, Wang F, Quek K, Wang C, Kheradmand F, Chen R, Chow CW, Lin H, Bernatchez C, Jalali A, Hu X, Wu CJ, Eterovic AK, Parra ER, Yusko E, Emerson R, Benzeno S, Vignali M, Wu X, Ye Y, Little LD, Gumbs C, Mao X, Song X, Tippen S, Thornton RL, Cascone T, Snyder A, Wargo JA, Herbst R, Swisher S, Kadara H, Moran C, Kalhor N, Zhang J, Scheet P, Vaporciyan AA, Sepesi B, Gibbons DL, Robins H, Hwu P, Heymach JV, Sharma P, Allison JP, Baladandayuthapani V, Lee JJ, Davis MM, Wistuba II, Futreal PA, Zhang J. Comprehensive T cell repertoire characterization of non-small cell lung cancer. Nat Commun 11(1):603, 2020. PMID: 32001676.
39. Wang S, Wang T, Yang L, Yang DM, Fujimoto J, Yi F, Luo X, Yang Y, Yao B, Lin SY, Moran CA, Kalhor N, Weissferdt A, Minna J, Xie Y, Wistuba II, Mao Y, Xiao G. ConvPath: A Software Tool for Lung Adenocarcinoma Digital Pathological Image Analysis Aided by a Convolutional Neural Network. EBiomedicine(50):103-110, 2019. e-Pub 2019. PMID: 31767541.
40. Chen Y, Zhang R, Wang L, Correa AM, Pataer A, Xu Y, Zhang X, Ren C, Wu S, Meng QH, Fujimoto J, Jensen VB, Antonoff MB, Hofstetter WL, Mehran RJ, Pisimisis G , Rice DC, Sepesi B, Vaporciyan AA, Walsh GL, Swisher SG , Roth JA, Heymach JV, Fang B. Tumor characteristics associated with engraftment of patient-derived non-small cell lung cancer xenografts in immunocompromised mice. Cancer 125(21):3738-3748, 2019. e-Pub 2019. PMID: 31287557.
41. Wang S, Yang DM, Rong R, Zhan X, Fujimoto J, Liu H, Minna J, Wistuba II, Xie Y, Xiao G. Artificial Intelligence in Lung Cancer Pathology Image Analysis. Cancers (Basel) 11(11):E-collection, 2019. PMID: 31661863.
42. Kadara H, Sivakumar S, Jakubek Y, San Lucas FA, Lang W, McDowell T, Weber Z, Behrens C, Davies GE, Kalhor N, Moran C, El-Zein R, Mehran R, Swisher SG, Wang J, Zhang J, Fujimoto J, Fowler J, Heymach JV, Dubinett S, Spira AE, Ehli EA, Wistuba II, Scheet P. Driver Mutations in Normal Airway Epithelium Elucidate Spatiotemporal Resolution of Lung Cancer. Am J Respir Crit Care Med 200(6):742-750, 2019. PMID: 30896962.
43. Kudo Y, Haymaker C, Zhang J Reuben A, Duose DY, Fujimoto J, Roy-Chowdhuri S, Solis LM, Dejima H, Parra-Cuentas ER, Mino B, Abraham R, Ikeda N, Vaporcyan AA, Gibbons DL, Zhang J, Lang Jr FF, Luthra R, Lee JJ, Moran CA, Huse JT, Kadara H, Wistuba II. Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer. Ann Oncol 30(9):1521-1530, 2019. PMID: 31282941.
44. Mitchell KG, Parra ER, Nelson DB, Zhang J, Wistuba II, Fujimoto J, Roth JA, Antonoff MB, MD Anderson Lung Cancer Immune Microenvironment Working Group. Tumor cellular proliferation is associated with enhanced immune checkpoint expression in stage I non-small cell lung cancer. J Thorac Cardiovasc Surg 158(3):911-919, 2019. PMID: 31235357.
45. Hu X*, Fujimoto J*, Ying L*(*co-first authors), Fukuoka J, Ashizawa K, Sun W, Reuben A, Chow CW, McGranahan N, Chen R, Hu J, Godoy M, Tabata K, Kuroda K, Shi L, Li J, Behrens C, Parra ER, Little LD, Gumbs C, Mao X, Song X, Tippen S, Thornton RL, Kadara H, Scheet P, Roarty E, Ostrin EJ, Wang X, Carter BW, Antonoff M, Zhang J, Vaporciyan AA, Pass H, Swisher S, Heymach JV, Lee JJ, Wistuba II, Hong WK, Futreal AP, Su D, Zhang J. Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma. Nat Commun 10(1):Article number: 2978. e-Pub 2019. PMID: 31278276.
46. Haynes BC, Blidner R, Cardwell R, Zeigler R, Gokul S, Thibert J, Chen L, Fujimoto J, Papadimitrakopoulou VA, Wistuba II, Latham GJ. An Integrated Next-Generation Sequencing System for Analyzing DNA Mutations, Gene Fusions, and RNA Expression in Lung Cancer. Transl Oncol 12(6):836-845, 2019. e-Pub 2019. PMID: 30981944.
47. Sen T, Rodriguez BL, Chen L, Della Corte C, Morikawa N, Fujimoto J, Cristea S, Nguyen T, Diao L, Li L, Fan Y, Yang Y, Wang J, Glisson BS, Wistuba II, Sage J, Heymach JV, Gibbons DL, Byers LA.. Targeting DNA damage response promotes anti-tumor immunity through STING-mediated T-cell activation in small cell lung cancer. Cancer Discov 9(5):646-661, 2019. e-Pub 2019. PMID: 30777870.
48. Luo X, Yin S, Yang L, Fujimoto J, Yang Y, Moran CA, Kalhor N, Weissferdt, A Xie Y, Gazdar AF, Minna JD, Wistuba II, Mao Y, Xiao G. Development and Validation of a Pathology Image Analysis-based Predictive Model for Lung Adenocarcinoma Prognosis - A Multi-cohort Study. Sci Rep 9(1):6886, 2019. PMID: 31053738.
49. Sivakumar S, San Lucas FA; Jakubek Y, McDowell TL, Lang W, Kallsen N, Peyton S, Davies GE, Fukuoka J, Yatabe Y, Zhang J, Futreal A, Fowler J, Fujimoto J, Ehli EA, Hawk ET, Wistuba II, Kadara H, Scheet P. Genomic landscape of allelic imbalance in premalignant atypical adenomatous hyperplasias of the lung. EBioMedicine(42):296-303, 2019. e-Pub 2019. PMID: 30905849.
50. Daouk R, Hassane M, Bahmad H, Sinjab A, Fujimoto J, Abou-Kheir W, Kadara H. Genome-Wide and Phenotypic Evaluation of Stem Cell Progenitors Derived from Murine Lung Adenocarcinoma with Somatic Kras Mutations. Front Oncol 9(207):eCollection 2019, 2019. e-Pub 2019. PMID: 31001473.
51. Weissferdt A, Kalhor N, Rodriguez Canales J, Fujimoto J, Wistuba II, Moran CA. Primary Mediastinal Yolk Sac Tumors: An Immunohistochemical Analysis of 14 Cases. Appl Immunohistochem Mol Morphol 27(2):125-133. e-Pub 2019. PMID: 27643524.
52. Hmeljak J, Sanchez-Vega F, Hoadley K, Cherniack A, Heiman D, Shih J, Stewart C, Danilova L, Tarpey P, Rehan Akbani, Kanchi R , Osmanbeyoglu H, Sekido Y, Takeshita J, Newton Y, Graim K, Gupta M, Anur P, Gay C, Dao L, Iype L, Travis WD, Dacic S, Chirieac L, Galateau-Sallé F, Fujimoto J, Hussain A, Silveira H, Rusch V, Kwiatkowski DJ, Rintoul R, Pass H, Kindler H, Creaney J, Lichtenberg T, Leraas K, Bowen J, TCGA Research Network, Felau I, Zenklusen JC, Severson D, Ravegnini G, Desmeules P, Jungbluth A, Byers L, Noble M, Gibb E, Bowlby R, Robertson G, Zauderer M, Tsao A, Drill E, Shen R, Bueno R, Fletcher J, Aburatani H, Robinson B, Campbell P, Ladanyi M. Integrative Molecular Characterization of Malignant Pleural Mesothelioma. Cancer Discov 8(12):1548-1565, 2018. PMID: 30322867.
53. Pozo K, Zahler S, Ishimatsu K, Carter AM, Telange R, Wang S, Pfragner R, Fujimoto J, Grubbs EG, Takahashi M, Oltmann SC, Bibb JA. Preclinical characterization of tyrosine kinase inhibitor-based targeted therapies for neuroendocrine thyroid cancer. Oncotarget 9(102):37662-37675, 2018. PMID: 30701022.
54. Khalil A, Dekmak B, Boulos F, Kantrowitz J, Spira A, Fujimoto J, Kadara H, El-Hachem N, Nemer G. Transcriptomic alterations in lung adenocarcinoma unveil new mechanisms targeted by the TBX2 subfamily of tumor suppressor genes. Front Oncol 8(482):eCollection 2018, 2018. PMID: 30425966.
55. Korkut A, Zaidi S, Kanchi RS, Rao S, Gough NR, Schultz A, Li X, Lorenzi PL, Berger AC, Robertson G, Kwong LN, Datto M, Roszik J, Ling S, Ravikumar V, Manyam G, Rao A, Shelley S, Liu Y, Ju Z, Hansel D, de Velasco G, Pennathur A, Andersen JB, O'Rourke CJ, Ohshiro K, Jogunoori W, Nguyen BN, Li S, Osmanbeyoglu HU, Ajani JA, Mani SA, Houseman A, Wiznerowicz M, Chen J, Gu S, Ma W, Zhang J, Tong P, Cherniack AD, Deng C, Resar L; Cancer Genome Atlas Research Network, Weinstein JN, Mishra L, Akbani R. A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β Superfamily. Cell Syst 7(4):422-437, 2018. PMID: 30268436.
56. Wang Y, Xu X, Maglic D, Dill MT, Mojumdar K, Ng PK, Jeong KJ, Tsang YH, Moreno D, Bhavana VH, Peng X, Ge Z, Chen H, Li J, Chen Z, Zhang H, Han L, Du D, Creighton CJ, Mills GB; Cancer Genome Atlas Research Network, Camargo F, Liang H. Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer. Cell Rep 25(5):1304-1317, 2018. PMID: 30380420.
57. Finnicum CT, Rahal Z, Hassane M, Treekitkarnmongkol W, Sinjab A, Morriss R, Viet S, Petersen JL, Lorenzi P, Tan L, Petrosino J, Hoffman K, Fujimoto J, Moghaddam SJ, Kadara H. Pathogenesis of Tobacco-Associated Lung Adenocarcinoma Is Closely Coupled with Changes in the Gut and Lung Microbiomes. Int J Mol Sci 23(18):10930, 2018. PMID: 36142843.
58. Kahles A, Lehmann KV, Toussaint NC, Hüser M, Stark SG, Sachsenberg T, Stegle O, Kohlbacher O, Sander C; Cancer Genome Atlas Research Network, Rätsch G.. Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients. Cancer Cell 34(2):211-224, 2018. PMID: 30078747.
59. Wang S, Chen A, Yang L, Cai L, Xie Y, Fujimoto J, Gazdar A, Xiao G. Comprehensive analysis of lung cancer pathology images to discover tumor shape and boundary features that predict survival outcome. Sci Rep 8(1):10393, 2018. e-Pub 2018. PMID: 29991684.
60. Lee WC, Diao L, Wang J, Zhang J, Roarty E, Varghese S, Chow CB, Fujimoto J, Behrens C, Cascone T, Peng W, Kalhor N, Moran CA, Weissferdt A, Johnson F, William WN, Swisher S, Heymach JV, Wistuba II, Futreal PA, Zhang J. Multiregion gene-expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer. Mod Pathol 31(6):947-955, 2018. e-Pub 2018. PMID: 29410488.
61. Pietanza MC, Waqar SN, Krug LM, Dowlati A, Hann C, Chiappori A, Owonikoko TK, Woo KM, Cardnell RJ, Fujimoto J, Long L, Diao L, Wang J, Bensman Y, Hurtado B, Sulman EP, Wistuba II, Piekarz R, Fleisher M, Heymach JV Kris MG, Rudin CM, Byers LA. A randomized, double blinded, phase II study of temozolomide in combination with either veliparib or placebo in patients with relapsed sensitive or refractory small cell lung cancer. J Clin Oncol 36(23):2386-2394, 2018. PMID: 29906251.
62. Tan X, Banerjee P, Liu X, Yu J, Gibbons DL, Wu P, ,Scott KL, Diao L, Wang J, Jalali A, Suraokar M, Fujimoto J, Behrens C, Liu X, Liu C, Creighton CJ, Wistuba II, Kurie JM. The epithelial-to-mesenchymal transition activator ZEB1 initiates a pro-metastatic competing endogenous RNA network. J Clin Invest 128(4):1267-1282, 2018. e-Pub 2018. PMID: 29324442.
63. Kantrowitz J, Sinjab A, Xu L, McDowell TL, Sivakumar S, Lang W, Nunomura-Nakamura S, Fukuoka J, Nemer G, Darwiche N, Chami H, Tfayli A, Wistuba II, Scheet P, Fujimoto J, Spira AE, Kadara H. Genome-wide expression changes in the normal-appearing airway during the evolution of smoking-associated lung adenocarcinoma. Cancer Prev Res (Phila) 11(4):237-248, 2018. PMID: 29382653.
64. Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, Ziv E, Culhane AC, Paull EO, Sivakumar IKA, Gentles AJ, Malhotra R, Farshidfar F, Colaprico A, Parker JS, Mose LE, Vo NS, Liu J, Liu Y, Rader J, Dhankani V, Reynolds SM, Bowlby R, Califano A, Cherniack AD, Anastassiou D, Bedognetti D, Rao A, Chen K, Krasnitz A, Hu H, Malta TM, Noushmehr H, Pedamallu CS, Bullman S, Ojesina AI, Lamb A, Zhou W, Shen H, Choueiri TK, Weinstein JN, Guinney J, Saltz J, Holt RA, Rabkin CE; Cancer Genome Atlas Research Network, Lazar AJ, Serody JS, Demicco EG, Disis ML, Vincent BG, Shmulevich L. The Immune Landscape of Cancer. Immunity 48(4):812-830, 2018. e-Pub 2018. PMID: 29628290.
65. Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, Kovatich AJ, Benz CC, Levine DA, Lee AV, Omberg L, Wolf DM, Shriver CD, Thorsson V; Cancer Genome Atlas Research Network, Hu H. An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell 173(2):400-416, 2018. PMID: 29625055.
66. Chen H, Li C, Peng X, Zhou Z, Weinstein JN; Cancer Genome Atlas Research Network, Liang H. A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples. Cell 173(2):386-399, 2018. PMID: 29625054.
67. Bailey MH, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A, Colaprico A, Wendl MC, Kim J, Reardon B, Ng PK, Jeong KJ, Cao S, Wang Z, Gao J, Gao Q, Wang F, Liu EM, Mularoni L, Rubio-Perez C, Nagarajan N, Cortés-Ciriano I, Zhou DC, Liang WW, Hess JM, Yellapantula VD, Tamborero D, Gonzalez-Perez A, Suphavilai C, Ko JY, Khurana E, Park PJ, Van Allen EM, Liang H; MC3 Working Group; Cancer Genome Atlas Research Network, Lawrence MS, Godzik A, Lopez-Bigas N, Stuart J, Wheeler D, Getz G, Chen K, Lazar AJ, Mills GB, Karchin R, Ding L. Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell 173(2):371-385, 2018. PMID: 29625053.
68. Malta TM, Sokolov A, Gentles AJ, Burzykowski T, Poisson L, Weinstein JN, Kamińska B, Huelsken J, Omberg L, Gevaert O, Colaprico A, Czerwińska P, Mazurek S, Mishra L, Heyn H, Krasnitz A, Godwin AK, Lazar AJ; Cancer Genome Atlas Research Network, Stuart JM, Hoadley KA, Laird PW, Noushmehr H, Wiznerowicz M. Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. Cell 173(2):338-354, 2018. PMID: 29625051.
69. Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, Dimitriadoy S, Liu DL, Kantheti HS, Saghafinia S, Chakravarty D, Daian F, Gao Q, Bailey MH, Liang WW, Foltz SM, Shmulevich I, Ding L, Heins Z, Ochoa A, Gross B, Gao J, Zhang H, Kundra R, Kandoth C, Bahceci I, Dervishi L, Dogrusoz U, Zhou W, Shen H, Laird PW, Way GP, Greene CS, Liang H, Xiao Y, Wang C, Iavarone A, Berger AH, Bivona TG, Lazar AJ, Hammer GD, Giordano T, Kwong LN, McArthur G, Huang C, Tward AD, Frederick MJ, McCormick F, Meyerson M; Cancer Genome Atlas Research Network, Van Allen EM, Cherniack AD, Ciriello G, Sander C, Schultz N. Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell 173(2):321-337, 2018. PMID: 29625050.
70. Ding L, Bailey MH, Porta-Pardo E, Thorsson V, Colaprico A, Bertrand D, Gibbs DL, Weerasinghe A, Huang KL, Tokheim C, Cortés-Ciriano I, Jayasinghe R, Chen F, Yu L, Sun S, Olsen C, Kim J, Taylor AM, Cherniack AD, Akbani R, Suphavilai C, Nagarajan N, Stuart JM, Mills GB, Wyczalkowski MA, Vincent BG, Hutter CM, Zenklusen JC, Hoadley KA, Wendl MC, Shmulevich L, Lazar AJ, Wheeler DA, Getz G; Cancer Genome Atlas Research Network. Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. Cell 173(2):305-320, 2018. PMID: 29625049.
71. Hoadley KA, Yau C, Hinoue T, Wolf DM, Lazar AJ, Drill E, Shen R, Taylor AM, Cherniack AD, Thorsson V, Akbani R, Bowlby R, Wong CK, Wiznerowicz M, Sanchez-Vega F, Robertson AG, Schneider BG, Lawrence MS, Noushmehr H, Malta TM; Cancer Genome Atlas Network, Stuart JM, Benz CC, Laird PW. Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. Cell 173(2):291-304, 2018. PMID: 29625048.
72. Liu Y, Sethi NS, Hinoue T, Schneider BG, Cherniack AD, Sanchez-Vega F, Seoane JA, Farshidfar F, Bowlby R, Islam M, Kim J, Chatila W, Akbani R, Kanchi RS, Rabkin CS, Willis JE, Wang KK, McCall SJ, Mishra L, Ojesina AI, Bullman S, Pedamallu CS, Lazar AJ, Sakai R; Cancer Genome Atlas Research Network, Thorsson V, Bass AJ, Laird PW. Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. Cancer Cell 33(4):721-735, 2018. PMID: 29622466.
73. Wang Z, Yang B, Zhang M, Guo W, Wu Z, Wang Y, Jia L, Li S; Cancer Genome Atlas Research Network, Xie W, Yang D. lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer. Cancer Cell 33(4):706-720, 2018. PMID: 29622465.
74. Berger AC, Korkut A, Kanchi RS, Hegde AM, Lenoir W, Liu W, Liu Y, Fan H, Shen H, Ravikumar V, Rao A, Schultz A, Li X, Sumazin P, Williams C, Mestdagh P, Gunaratne PH, Yau C, Bowlby R, Robertson AG, Tiezzi DG, Wang C, Cherniack AD, Godwin AK, Kuderer NM, Rader JS, Zuna RE, Sood AK, Lazar AJ, Ojesina AI, Adebamowo C, Adebamowo SN, Baggerly KA, Chen TW, Chiu HS, Lefever S, Liu L, MacKenzie K, Orsulic S, Roszik J, Shelley CS, Song Q, Vellano CP, Wentzensen N; Cancer Genome Atlas Research Network, Weinstein JN, Mills GB, Levine DA, Akbani R. A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. Cancer Cell 33(4):690-705, 2018. PMID: 29622464.
75. Taylor AM, Shih J, Ha G, Gao GF, Zhang X, Berger AC, Schumacher SE, Wang C, Hu H, Liu J, Lazar AJ; Cancer Genome Atlas Research Network, Cherniack AD, Beroukhim R, Meyerson M. Genomic and Functional Approaches to Understanding Cancer Aneuploidy. Cancer Cell 33(4):690-705, 2018. PMID: 29622463.
76. Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, Bowlby R, Gibb EA, Akbani R, Beroukhim R, Bottaro DP, Choueiri TK, Gibbs RA, Godwin AK, Haake S, Hakimi AA, Henske EP, Hsieh JJ, Ho TH, Kanchi RS, Krishnan B, Kwaitkowski DJ, Lui W, Merino MJ, Mills GB, Myers J, Nickerson ML, Reuter VE, Schmidt LS, Shelley CS, Shen H, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Vincent BG, Vocke CD, Wheeler DA, Yang L, Kim WT, Robertson AG; Cancer Genome Atlas Research Network, Spellman PT, Rathmell WK, Linehan WM. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Rep 23(1):313-326, 2018. PMID: 29617669.
77. Chiu HS, Somvanshi S, Patel E, Chen TW, Singh VP, Zorman B, Patil SL, Pan Y, Chatterjee SS; Cancer Genome Atlas Research Network, Sood AK, Gunaratne PH, Sumazin P. Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context. Cell Rep 23(1):297-312, 2018. PMID: 29617668.
78. Seiler M, Peng S, Agrawal AA, Palacino J, Teng T, Zhu P, Smith PG; Cancer Genome Atlas Research Network, Buonamici S, Yu L. Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types. Cell Rep 23(1):282-296, 2018. PMID: 29617667.
79. Jayasinghe RG, Cao S, Gao Q, Wendl MC, Vo NS, Reynolds SM, Zhao Y, Climente-González H, Chai S, Wang F, Varghese R, Huang M, Liang WW, Wyczalkowski MA, Sengupta S, Li Z, Payne SH, Fenyö D, Miner JH, Walter MJ; Cancer Genome Atlas Research Network, Vincent B, Eyras E, Chen K, Shmulevich I, Chen F, Ding L. Systematic Analysis of Splice-Site-Creating Mutations in Cancer. Cell Rep 23(1):270-281, 2018. PMID: 29617666.
80. Peng X, Chen Z, Farshidfar F, Xu X, Lorenzi PL, Wang Y, Cheng F, Tan L, Mojumdar K, Du D, Ge Z, Li J, Thomas GV, Birsoy K, Liu L, Zhang H, Zhao Z, Marchand C, Weinstein JN; Cancer Genome Atlas Research Network, Bathe OF, Liang H. Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers. Cell Rep 23(1):255-269, 2018. PMID: 29617665.
81. Knijnenburg TA, Wang L, Zimmermann MT, Chambwe N, Gao GF, Cherniack AD, Fan H, Shen H, Way GP, Greene CS, Liu Y, Akbani R, Feng B, Donehower LA, Miller C, Shen Y, Karimi M, Chen H, Kim P, Jia P, Shinbrot E, Zhang S, Liu J, Hu H, Bailey MH, Yau C, Wolf D, Zhao Z, Weinstein JN, Li L, Ding L, Mills GB, Laird PW, Wheeler DA, Shmulevich I; Cancer Genome Atlas Research Network, Monnat RJ Jr., Xiao Y, Wang C. Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. Cell Rep 23(1):239-254, 2018. PMID: 29617664.
82. Gao Q, Liang WW, Foltz SM, Mutharasu G, Jayasinghe RG, Cao S, Liao WW, Reynolds SM, Wyczalkowski MA, Yao L, Yu L, Sun SQ; Fusion Analysis Working Group; Cancer Genome Atlas Research Network, Chen K, Lazar AJ, Fields RC, Wendl MC, Van Tine BA, Vij R, Chen F, Nykter M, Shmulevich I, Ding L. Driver Fusions and Their Implications in the Development and Treatment of Human Cancers. Cell Rep 23(1):227-238, 2018. PMID: 29617662.
83. Ge Z, Leighton JS, Wang Y, Peng X, Chen Z, Chen H, Sun Y, Yao F, Li J, Zhang H, Liu J, Shriver CD, Hu H; Cancer Genome Atlas Research Network, Piwnica-Worms H, Ma L, Liang H. Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types. Cell Rep 23(1):213-226, 2018. PMID: 29617661.
84. Campbell JD, Yau C, Bowlby R, Liu Y, Brennan K, Fan H, Taylor AM, Wang C, Walter V, Akbani R, Byers LA, Creighton CJ, Coarfa C, Shih J, Cherniack AD, Gevaert O, Prunello M, Shen H, Anur P, Chen J, Cheng H, Hayes DN, Bullman S, Pedamallu CS, Ojesina AI, Sadeghi S, Mungall KL, Robertson AG, Benz C, Schultz A, Kanchi RS, Gay CM, Hegde A, Diao L, Wang J, Ma W, Sumazin P, Chiu HS, Chen TW, Gunaratne P, Donehower L, Rader JS, Zuna R, Al-Ahmadie H, Lazar AJ, Flores ER, Tsai KY, Zhou JH, Rustgi AK, Drill E, Shen R, Wong CK; Cancer Genome Atlas Research Network, Stuart JM, Laird PW, Hoadley KA, Weinstein JN, Peto M, Pickering CR, Chen Z, Van Waes C. Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. Cell Rep 23(1):194-212, 2018. PMID: 29617660.
85. Saltz J, Gupta R, Hou L, Kurc T, Singh P, Nguyen V, Samaras D, Shroyer KR, Zhao T, Batiste R, Van Arnam J; Cancer Genome Atlas Research Network, Shmulevich I, Rao AUK, Lazar AJ, Sharma A, Thorsson V. Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images. Cell Rep 23(1):181-193, 2018. PMID: 29617659.
86. Way GP, Sanchez-Vega F, La K, Armenia J, Chatila WK, Luna A, Sander C, Cherniack AD, Mina M, Ciriello G, Schultz N; Cancer Genome Atlas Research Network, Sanchez Y, Greene CS. Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas. Cell Rep 23(1):172-180, 2018. PMID: 29617658.
87. Aisner DL, Sholl LM, Berry LD, Rossi M, Chen H, Fujimoto J, Moreira A, Ramalingam SS, Villaruz L, Otterson G, Haura E, Politi K, Glisson B, Cetnar J, Garon E, Schiller J, Waqar S, Sequist L, Brahmer J, LCMC2 investigators, Shyr Y, Kugler K, Wistuba II, Johnson BE, Minna JD, Kris MG, Bunn PA, Kwiatkowski DJ. The Impact of Smoking and TP53 mutations in lung adenocarcinoma patients with targetable mutations – the Lung Cancer Mutation Consortium (LCMC2). Clin Cancer Res 24(5):1038-1047, 2018. e-Pub 2017. PMID: 29217530.
88. Barua S, Fang P, Sharma A, Fujimoto J, Wistuba II, Rao AUK, Lin SH. Spatial interaction of tumor cells and regulatory T cells correlates with survival in non-small cell lung cancer. Lung Cancer(117):73-79, 2018. e-Pub 2018. PMID: 29409671.
89. Schaub FX, Dhankani V, Berger AC, Trivedi M, Richardson AB, Shaw R, Zhao W, Zhang X, Ventura A, Liu Y, Ayer DE, Hurlin PJ, Cherniack AD, Eisenman RN, Bernard B, Grandori C; Cancer Genome Atlas Network. Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas. Cell Syst 6(3):282-300, 2018. PMID: 29596783.
90. Ellrott K, Bailey MH, Saksena G, Covington KR, Kandoth C, Stewart C, Hess J, Ma S, Chiotti KE, McLellan M, Sofia HJ, Hutter C, Getz G, Wheeler D, Ding L; MC3 Working Group; Cancer Genome Atlas Research Network. Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. Cell Syst 6(3):271-281, 2018. PMID: 29596782.
91. Tsao AS, Lin H, Carter B, Lee JJ, Rice D, Vaporcyan A,Swisher S, Mehran R, Heymach JV, Nilsson M, Fan Y, Nunez M, Diao L, Wang J, Fujimoto J, Wistuba II, Hong WK. Biomarker-Integrated Phase I Trial of Neoadjuvant Dasatinib in Resectable Malignant Pleural Mesothelioma. J Thorac Oncol 13(2):246-257, 2018. e-Pub 2017. PMID: 29313814.
92. Radovich M, Pickering C, Felau I, Ha G, Zhang H, Jo H, Hoadley K, Anur P, Zhang J, McLellan M, Bowlby R, Matthew T, Danilova L, Hegde A, Leiserson M, Sethi G, Lu C, Ryan M, Su X, Cherniak A, Robertson G, Akbani R, Spellman P, Weinstein J, Hayes N, Raphael B, Lichtenberg T, Leraas K, Zenklusen JC, Fujimoto J, Neto C, Moreira A, Hwang D, Huang J, Marino M, Korst R, Giaccone G, Gokmen-Polar Y, Badve S, Rajan A, Strobel P, Girard N, Tsao M, Marx A, Tsao A, Loehrer P. The integrated genomic landscape of thymic epithelial tumors. Cancer Cell 33(2):244-258, 2018. PMID: 29438696.
93. Wang Y, Gudikote J, Giri U, Yan J, Deng W, Ye R, Jiang W, Li N, Hobbs BP, Wang J, Swisher SG, Fujimoto J, Wistuba II, Komaki R, Heymach JV, Lin SH. RAD50 expression is associated with poor clinical outcomes after radiotherapy for resected non-small cell lung cancer. Clin Cancer Res 24(2):341-350, 2018. e-Pub 2017. PMID: 29030353.
94. Sivakumar S, San Lucas FA, McDowell TL, Lang W, Xu L, Fujimoto J, Zhang J, Wistuba II, Futreal FA, Fukuoka J, Yatabe Y, Dubinett S, Spira A, Fowler J, Hawk E, Scheet P, Kadara H. Genomic landscape of atypical adenomatous hyperplasia reveals divergent modes to lung adenocarcinoma. Cancer Res 77(22):6119-6130, 2017. PMID: 28951454.
95. Fujimoto J, Nunomura-Nakamura S, Liu Y, Lang W, McDowell T, Jakubek Y, Ezzeddine D, Ochieng JK, Petersen J, Davies G, Fukuoka J, Wistuba II, Ehli E, Fowler J, Scheet P, Kadara H. Development of Kras mutant lung adenocarcinoma in mice with knockout of the airway lineage-specific gene Gprc5a. Int J Cancer (*Cover of Int J Cancer) 141(8):1589-1599, 2017. PMID: 28653505.
96. Zhao X, Huffman KE, Fujimoto J, Canales JR, Girard L, Nie G, Heymach JV, Wistuba II, Minna JD, Yu Y. Quantitative proteomic analysis of optimal cutting temperature (OCT) embedded core needle biopsy of lung cancer. J Am Soc Mass Spectrom 28(10):2078-2089, 2017. e-Pub 2017. PMID: 28752479.
97. Vykoukal J, Sun N, Aguilar-Bonavides C, Katayama H, Tanaka I, Fahrmann JF, Capello M, Fujimoto J, Aguilar M, Wistuba II, Taguchi A, Ostrin EJ, Hanash SM. Plasma-derived extracellular vesicle proteins as a source of biomarkers for lung adenocarcinoma. Oncotarget 8(56):95466-95480, 2017. PMID: 29221141.
98. Cardnell RJ, Li L, Bara R, Tong P, Fujimoto J, Banerjee U, Kalu NN, Fan Y, Johnson FM, Wistuba II, Heymach JV, Wang J, Byers LA. Protein expression of TTF1 and cMyc define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies. Oncotarget 8(43):73419-73432, 2017. PMID: 29088717.
99. Byers LA, Horn L, Gandhi J, Kloecker G, Owonikoko TK, Waqar S, Krzakowski M, Cardnell RJG, Fujimoto J, Taverna P, Azab M, Camidge DR. A Phase 2, Open-Label, Multi-Center Study of Amuvatinib in Combination with Platinum Etoposide Chemotherapy in Platinum Refractory Small Cell Lung Cancer Patients. Oncotarget 8(46):81441-81454, 2017. PMID: 29113403.
100. Rimm DL, Han G, Taube JM, Yi ES, Bridge JA, Flieder DB, MD, Homer R, West WW, Wu H, Roden AC, Fujimoto J, Yu H, Anders R, Kowalewski A, Rivard C, Rehman J, Batenchuk C, Burns V, Hirsch FR, Wistuba II. A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer. JAMA Oncol 3(8):1051-1058, 2017. PMID: 28278348.
101. Khalil AA, Sivakumar S, San Lucas FA, McDowell T, Lang W, Tabata K, Fujimoto J, Yatabe Y, Spira A, Scheet P, Nemer G, Kadara H. TBX2 subfamily suppression in lung cancer pathogenesis: a high-potential marker for early detection. Oncotarget 8(40):68230-68241, 2017. PMID: 28978111.
102. Reuben A, Gittelman R, Gao J, Zhang J, Yusko EC, Wu CJ, Emerson R, Zhang J, Tipton C, Cascone T, Vignali M, Fujimoto J, Rodriguez JC, Parra Cuentas ER, Forget MA, Federico L, Haymaker C, Behrens C, Benzeno S, Bernatchez C, Gibbons DL, Wargo JA, Swisher S, Heymach JV, Robins H, Lee JJ, Futreal A, Wistuba II, Zhang J. TCR repertoire intratumor heterogeneity in localized lung adenocarcinomas: an association with predicted neoantigen heterogeneity and postsurgical recurrence. Cancer Discov, 2017. e-Pub 2017. PMID: 28733428.
103. Stewart CA, Tong P, Cardnell RJ, Sen T, Li L, Gay CM, Masrorpour F, Fan Y, Bara RO, Feng Y, Ru Y, Fujimoto J, Kundu ST, Post LE, Yu GK, Shen Y, Glisson BS, Wistuba II, Heymach JV, Gibbons DL, Wang J, Byers LA. Dynamic Variations in Epithelial-to-Mesenchymal Transition (EMT), ATM, and SLFN11 Govern Response to PARP inhibitors and Cisplatin in Small Cell Lung Cancer. Oncotarget 8(27):28575-28587, 2017. e-Pub 2017. PMID: 28212573.
104. Kadara H, Choi M, Zhang J, Cuentas EP, Canales JR, Gaffney SG, Zhao ZM, Behrens C, Fujimoto J, Chow CW, Yoo Y, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons DL, Heymach J, Kaftan E, Townsend JP, Lynch TJ, Schlessinger J, Lee JJ, Lifton RP, Wistuba II, Herbst RS. Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up. Ann Oncol 28(1):75-82, 2017. e-Pub 2017. PMID: 27687306.
105. Quek K, Li J, Estecio M, Zhang J, Fujimoto J, Little L, Chow CW, Song X, Behrens C, Chen T, William Jr. WN, Swisher S, Heymach JV, Wistuba II, Zhang J, Futreal PA, Zhang J. DNA methylation intratumor heterogeneity in localized lung adenocarcinomas. Oncotarget 8(13):21994–22002, 2017. PMID: 28423542.
106. Weissferdt A, Fujimoto J, Kalhor N, Rodriguez J, Wistuba II, Moran CA. Expression of PD-1 and PD-L1 in thymic epithelial neoplasms. Mod Pathol, 2017. e-Pub 2017. PMID: 28281549.
107. Choi M, Kadara H, Zhang J, Cuentas EP, Canales JR, Zhao ZM, Behrens C, Fujimoto J, Chow CW, Kim K, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons DL, Heymach J, Kaftan E, Townsend J, Lynch TJ, Schlessinger J, Lee JJ, Lifton RP, Herbst RS, Wistuba II. Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function. Ann Oncol 28(1):83-89, 2017. PMID: 28177435.
108. Weissferdt A, Kalhor N, Rodriguez-Canales J, Fujimoto J, Wistuba II, Moran CA. Spindle cell and pleomorphic ("sarcomatoid") carcinomas of the lung: an immunohistochemical analysis of 86 cases. Hum Pathol(59):1-9, 2017. e-Pub 2016. PMID: 27569293.
109. Miller AD, Heras MD, Yu J, Zhang F, Liu SL, Vaughan AE, Vaughan TL, Rosadio R, Rocca S, Palmieri G, Goedert JJ, Fujimoto J, Wistuba II. Evidence against a role for jaagsiekte sheep retrovirus in human lung cancer. Retrovirology 14(1):Article number: 3. e-Pub 2017. PMID: 28107820.
110. Liu Y, Zhang J, Li L, Yin G, Zhang J, Zheng S, Cheung H, Wu N, Lu N, Mao X, Yang L, Zhang J, Zhang L, Seth S, Chen H, Song X, Liu K, Xie Y, Zhou L, Zhao C, Han N, Chen W, Zhang S, Chen L, Cai W, Li L, Shen M, Xu N, Cheng S, Yang H, Lee JJ, Correa A, Fujimoto J, Behrens C, Chow CW, William WN, Heymach JV, Hong WK, Swisher S, Wistuba II, Wang J, Lin D, Liu X, Futreal PA, Gao Y. Genomic heterogeneity of multiple synchronous lung cancer. Nat Commun(7):Article number: 13200. e-Pub 2016. PMID: 27767028.
111. Jakubek Y, Lang W, Vattathil S, Garcia M, Xu L, Huang L, Yoo SY, Shen L, Lu W, Chow CW, Weber Z, Davies G, Huang J, Behrens C, Kalhor N, Moran C, Fujimoto J, Mehran R, El-Zein R, Swisher SG, Wang J, Fowler J, Spira AE, Ehli EA, Wistuba II, Scheet P, Kadara H. The genomic landscape of allelic imbalance in the normal-appearing airway field of cancerization. Cancer Res 76(13):3676-83, 2016. e-Pub 2016. PMID: 27216194.
112. Zhang YA, Ma X, Sathe A, Fujimoto J, Wistuba II, Lam S, Yatabe Y, Wang YW, Stastny V, Gao B, Larsen J, Girard L, Liu X, Song K, Xie Y, Zhang MQ, Minna JD, Gazdar AF. Validation of SCT Methylation As a Hallmark Biomarker for Lung Cancers. J Thorac Oncol 11(3):346-360. e-Pub 2015. PMID: 26725182.
113. Maki Y*, Fujimoto J*(*co-first authors), Lang W, Xu L, Behrens C, Wistuba II, Kadara H. LAPTM4B is associated with poor prognosis in NSCLC and promotes the NRF2-mediated stress response pathway in lung cancer cells. Sci Rep(5):Article number: 13846. e-Pub 2015. PMID: 26343532.
114. Sholl LM, Aisner DL, Varella-Garcia M, Berry LD, Dias-Santagata D, Wistuba II, Chen H, Fujimoto J, Kugler K, Franklin WA, Iafrate AJ, Ladanyi M, LCMC investigators, Kwiatkowski DJ. Multi-institutional driver mutation analysis in lung adenocarcinoma: The Lung Cancer Mutation Consortium experience. J Thorac Oncol 10(5):768-777, 2015. PMID: 25738220.
115. Weissferdt A, Canales JR, Liu H, Fujimoto J, Wistuba II, Moran CA. Primary mediastinal seminomas: a comprehensive immunohistochemical study with a focus on novel markers. Hum Pathol 46(3):376-383, 2015. PMID: 25576290.
116. Weissferdt A, Kalhor N, Liu H, Rodriguez J, Fujimoto J, Tang X, Wistuba II, Moran CA. Thymic neuroendocrine tumors (paraganglioma and carcinoid tumors): a comparative immunohistochemical study of 46 cases. Hum Pathol 45(12):2463-2470, 2014. PMID: 25294372.
117. Augustyn A, Borromeo M, Wang T, Fujimoto J, Shao C, Dospoy PD, Lee V, Tan C, Sullivan JP, Larsen JE, Girard L, Behrens C, Wistuba II, Xie Y, Cobb MH, Gazdar AF, Johnson JE, Minna JD. ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers. Proc Natl Acad Sci U S A 111(41):14788-14793, 2014. PMID: 25267614.
118. Zhang J, Fujimoto J, Zhang J, Wedge DC, Song X, Zhang J, Seth S, Chow CW, Cao Y, Gumbs C, Gold KA, Kalhor N, Little L, Mahadeshwar H, Moran C, Protopopov A, Sun H, Tang J, Wu X, Ye Y, William WN, Lee JJ, Heymach JV, Hong WK, Swisher S, Wistuba II, Futreal PA. Intra-tumor Heterogeneity in Localized Lung Adenocarcinomas Delineated by Multi-region Sequencing. Science 346(6206):256-9, 2014. PMID: 25301631.
119. Kim ES, Tang X, Peterson DR, Kilari D, Chow CW, Fujimoto J, Kalhor N, Swisher SG, Stewart DJ, Wistuba II, Siddik ZH. Copper Transporter CTR1 Expression and Tissue Platinum Concentration in Non-Small Cell Lung Cancer. Lung Cancer 85(1):88-93, 2014. e-Pub 2014. PMID: 24792335.
120. Tsao AS, Harun N, Fujimoto J, Devito V, Lee JJ, Kuhn E, Mehran R, Rice D, Moran C, Hong WK, Shen L, Suraokar M, Wistuba I. Elevated PDGFRB gene copy number gain is prognostic for improved survival outcomes in resected malignant pleural mesothelioma. Ann Diagn Pathol 18(3):140-145, 2014. e-Pub 2014. PMID: 24747001.
121. Tsao AS, Harun N, Lee JJ, Heymach J, Pisters K, Hong WK, Fujimoto J, Wistuba I. Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma. Clin Lung Cancer 15(3):197-201, 2014. e-Pub 2013. PMID: 24492162.
122. Kadara H, Fujimoto J, Yoo SY, Maki Y, Gower AC, Kabbout M, Garcia MM, Chow CW, Chu Z, Mendoza G, Shen L, Kalhor N, Hong WK, Moran C, Wang J, Spira A, Coombes KR, Wistuba II. Transcriptomic architecture of the adjacent airway field cancerization in nonsmall cell lung cancer. J Natl Cancer Inst 106(3):dju004, 2014. e-Pub 2014. PMID: 24563515.
123. Liu H, Tang X, Fujimoto J, Rodriguez J. Laser Capture Microdissection for the Investigative Pathologist. Vet Pathol 51(1):2463-2470, 2014. PMID: 24227008.
124. Wistuba II, Behrens C, Lombardi F, Wagner S, Fujimoto J, Raso MG, Spaggiari L, Galetta D, Riley R, Hughes E, Reid J, Sangale Z, Swisher SG, Kalhor N, Moran CA, Gutin A, Lanchbury JS, Barberis M, Kim ES. Validation of a Proliferation-based Expression Signature as Prognostic Marker in Early Stage Lung Adenocarcinoma. Clin Cancer Res 19(22):6261-6271, 2013. e-Pub 2013. PMID: 24048333.
125. Kabbout M, Garcia MM, Fujimoto J, Liu DD, Woods D, Chow CW, Mendoza G, Momin AA, James BP, Solis L, Behrens C, Lee JJ, Wistuba II, Kadara H. ETS2 mediated tumor suppressive function and MET oncogene inhibition in human non-small cell lung cancer. Clin Cancer Res 19(13):3383-3395, 2013. e-Pub 2013. PMID: 23659968.
126. Yang Z, Guan B, Men T, Fujimoto J, Xu X. Comparable molecular alterations in 4-nitroquinoline 1-ooxide induced oral and esophageal cancer in mice and in human esophageal cancer, associated with poor prognosis of patients. In Vivo 27(4):473-484, 2013. PMID: 23812217.
127. Kadara H, Shen L, Fujimoto J, Saintigny P, Chow CW, Lang W, Chu Z, Garcia M, Kabbout M, Fan YH, Behrens C, Liu DA, Mao L, Lee JJ, Gold KA, Wang J, Coombes KR, Kim ES, Hong WK, Wistuba II. Characterizing the molecular spatial and temporal field of injury in early stage smoker non-small cell lung cancer patients after definitive surgery by expression profiling. Cancer Prev Res (Phila) 6(1):8-17, 2013. e-Pub 2012. PMID: 23087048.
128. Fujimoto J, Kadara H, Garcia MM, Kabbout M, Behrens C, Liu DD, Lee JJ, Solis LM, Kim ES, Kalhor N, Moran C, Sharafkhaneh A, Lotan R, Wistuba II. G-protein coupled receptor family C group 5 member A (GPRC5A) expression is decreased in the adjacent field and normal bronchial epithelia of patients with chronic obstructive pulmonary disease and non-small cell lung cancer. J Thorac Oncol 7(12):1747-54, 2012. PMID: 23154545.
129. Kim ES, Lee JJ, He G, Chow CW, Fujimoto J, Kalhor N, Swisher SG, Wistuba II, Stewart DJ, Siddik ZH. Tissue Platinum Concentration and Tumor Response in Non-small Cell Lung Cancer. J Clin Oncol 30(27):3345-52, 2012. e-Pub 2012. PMID: 22891266.
130. Byers LA, Wang J, Nilsson MB, Fujimoto J, Saintigny P, Yordy J, Giri U, Peyton M, Fan YH, Diao L, Masrorpour F, Shen L, Liu W, Duchemann B, Tumula P, Bhardwaj V, Welsh J, Weber S, Glisson BS, Kalhor N, Wistuba II, Girard L, Lippman SM, Mills GB, Coombes KR, Weinstein JN, Minna JD, Heymach JV. Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1. Cancer Discov 2(9):798-811, 2012. e-Pub 2012. PMID: 22961666.
131. Weissferdt A, Lin H, Woods D, Tang X, Fujimoto J, Wistuba II, Moran CA. HER family receptor and ligand status in thymic carcinoma. Lung Cancer 77(3):515-521, 2012. e-Pub 2012. PMID: 22726920.
132. Tsao AS, Liu S, Fujimoto J, Wistuba II, Lee JJ, Marom EM, Charnsangavej C, Fossella FV, Tran HT, Blumenschein GR, Papadimitrakopoulou V, Kies MS, Hong WK, Stewart DJ. Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma. J Thorac Oncol 6(12):2104-2111, 2011. e-Pub 2011. PMID: 21892101.
133. Tang X, Kadara H, Behrens C, Liu DD, Xiao Y, Rice D, Gazdar AF, Fujimoto J, Moran C, Varella-Garcia M, Lee JJ, Hong WK, Wistuba II. Abnormalities of the TITF-1 lineage-specific oncogene in NSCLC: Implications in lung cancer pathogenesis and prognosis. Clin Cancer Res 17(8):2434-43, 2011. e-Pub 2011. PMID: 21257719.
134. Chen Y, Deng J, Fujimoto J, Kadara H, Men T, Lotan D, Lotan R. Gprc5a deletion enhances the transformed phenotype in normal and malignant lung epithelial cells by eliciting persistent Stat3 signaling induced by autocrine Lif. Cancer Res 70(21):8917-8926, 2010. e-Pub 2010. PMID: 20959490.
135. Fujimoto J, Kong M, Lee JJ, Hong WK, Lotan R. Validation of a Novel Statistical Model for Assessing the Synergy of Combined-agent Cancer Chemoprevention. Cancer Prev Res (Phila) (*Cover of Cancer Prev Res) 3(8):917-928, 2010. e-Pub 2010. PMID: 20663979.
136. Kadara H, Fujimoto J, Men T, Ye X, Lotan D, Lee JS, Lotan R. A Gprc5a tumor suppressor loss of expression signature is conserved, prevalent and associated with survival in human lung adenocarcinomas. Neoplasia 12(6):499-505, 2010. e-Pub 2010. PMID: 20563252.
137. Deng J*, Fujimoto J*(*co-first authors), Ye XF, Men TT, Van Pelt CS, Chen YL, Lin XF, Kadara H, Tao Q, Lotan D, Lotan R. Knockout of the Tumor Suppressor Gene Gprc5a in Mice Leads to NF-{kappa}B Activation in Airway Epithelium and Promotes Lung Inflammation and Tumorigenesis. Cancer Prev Res (Phila) (*Commentary in the same issue of Cancer Prev Res) 3(4):424-37, 2010. e-Pub 2010. PMID: 20354164.
138. Yuan P, Kadara H, Behrens C, Tang X, Woods D, Solis LM, Huang J, Spinola M, Dong W, Yin G, Fujimoto J, Kim E, Xie Y, Girard L, Moran C, Hong WK, Minna JD, Wistuba II. Sex determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung. PLoS One 5(2):e9112, 2010. PMID: 20161759.
139. Fujimoto J, Kadara H, Men T, van Pelt C, Lotan D, Lotan R. Comparative Functional Genomics Analysis of NNK Tobacco-Carcinogen Induced Lung Adenocarcinoma Development in Gprc5a-Knockout Mice. PLoS One 5(7):e11847, 2010. PMID: 20686609.
140. Tao Q, Fujimoto J, Men T, Ye X, Deng J, Lacroix L, Clifford JL, Mao L, Van Pelt CS, Lee JJ, Lotan D, Lotan R. Identification of the retinoic acid-inducible Gprc5a as a new lung tumor suppressor gene. J Natl Cancer Inst (*Commentary in the same issue of J Natl Cancer Inst) 99(22):1668-82, 2007. PMID: 18000218.
141. Tahara M, Ochiai A, Fujimoto J, Boku N, Yasui W, Ohtsu A, Tahara E, Yoshida S. Expression of thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase, E2F-1, Bak, Bcl-X, and Bcl-2, and clinical outcomes for gastric cancer patients treated with bolus 5-fluorouracil. Oncol Rep 11(1):9-15, 2004. PMID: 14654896.
142. Fujimoto J, Yasui W, Tahara H, Tahara E, Kudo Y, Yokozaki H, Tahara E. DNA hypermethylation at the pS2 promoter region is associated with early stage of stomach carcinogenesis. Cancer Lett 149(1-2):125-34, 2000. PMID: 10737716.
143. Yasui W, Yokozaki H, Fujimoto J, Naka K, Kuniyasu H, Tahara E. Genetic and epigenetic alterations in multistep carcinogenesis of the stomach. J Gastroenterol 35 Suppl(12):111-5, 2000. PMID: 10779229.
144. Yokozaki H, Shitara Y, Fujimoto J, Hiyama T, Yasui W, Tahara E. Alterations of p73 preferentially occur in gastric adenocarcinomas with foveolar epithelial phenotype. Int J Cancer 83(2):192-6, 1999. PMID: 10471526.
145. Yasui W, Naka K, Suzuki T, Fujimoto J, Hayashi K, Matsutani N, Yokozaki H, Tahara E. Expression of p27Kip1, cyclin E and E2F-1 in primary and metastatic tumors of gastric carcinoma. Oncol Rep 6(5):983-7, 1999. PMID: 10425291.
146. Yasui W, Fujimoto J, Suzuki T, Ono S, Naka K, Yokozaki H, Tahara E. Expression of cell-cycle-regulating transcription factor E2F-1 in colorectal carcinomas. Pathobiology 67(4):174-9, 1999. PMID: 10738178.
147. Yasui W, Tahara E, Tahara H, Fujimoto J, Naka K, Nakayama J, Ishikawa F, Ide T, Tahara E. Immunohistochemical detection of human telomerase reverse transcriptase in normal mucosa and precancerous lesions of the stomach. Jpn J Cancer Res 90(6):589-95, 1999. PMID: 10429648.
148. Tahara H, Yasui W, Tahara E, Fujimoto J, Ito K, Tamai K, Nakayama J, Ishikawa F, Tahara E, Ide T. Immuno-histochemical detection of human telomerase catalytic component, hTERT, in human colorectal tumor and non-tumor tissue sections. Oncogene 18(8):1561-7, 1999. PMID: 10102626.
149. Yokozaki H, Semba S, Fujimoto J, Tahara E. Microsatellite instabilities in gastric cancer patients with multiple primary cancers. Int J Oncol 14(1):151-5, 1999. PMID: 9863022.
150. Yasui W, Tahara H, Tahara E, Fujimoto J, Nakayama J, Ishikawa F, Ide T, Tahara E. Expression of telomerase catalytic component, telomerase reverse transcriptase, in human gastric carcinomas. Jpn J Cancer Res 89(11):1099-103, 1998. PMID: 9914776.
151. Yasui W, Kudo Y, Naka K, Fujimoto J, Ue T, Yokozaki H, Tahara E. Expression of CD44 containing variant exon 9 (CD44v9) in gastric adenomas and adenocarcinomas: relation to the proliferation and progression. Int J Oncol 12(6):1253-8, 1998. PMID: 9592182.

Invited Articles

1. Fujimoto J, Wistuba II. Current concepts on the molecular pathology of non-small cell lung cancercarcinoma. Semin Diagn Pathol 31(4):306-13, 2014. e-Pub 2014. PMID: 25239274.
2. Fujimoto J, Wistuba II. Updated Comprehensive Cancer Research Project in United States. -Challenges at University of Texas M.D. Anderson Cancer Center Thoracic Molecular Pathology Lab-. Nihon Rinsho (Japanese), 2013.

Other Articles

1. Katayama N, Yamamoto M, Ihara A, Fujimoto J, Kanazawa S A case of idiopathic thorombocytopenic purpura treated by splenic irradiation. Journal of JASTRO (Japanese Society for Therapeutic Radiology and Oncology) 17(1):35-39, 2005.
2. Ishida K, Taniyama K, Toda T, Fujimoto K, Murakami K, Motoshita J, Fujimoto J A very fast cell transfer method using a microwave with special references to several stainings and FISH. Journal of the Japanese Society of Clinical Cytology 44(6):353-359, 2005.
3. Nishi Y, Shirane M, Date T, Nishiura T, Fujimoto J Case of NK/T-cell lymphoma of the larynx with hemophagocytic syndrome. Nippon Jibiinkoka Gakkai Kaiho 107(10):966-969, 2004. PMID: 15559300.
4. Kaneko S, Madokoro N, Nakano K, Muramkami K, Fujimoto J, Taniyama K An Autopsy Case of Dermatomyositis with Severe Dysphagia. Nishinihon Journal of Dermatology 66(3):232-235, 2004.

Abstracts

1. Zhu B, Li JR, Chen H, Chen P, Fujimoto J, Tian Y, Aminu M, Li C, Reuben A, Edwin P, Shi O, Nilsson M, Pottete A, Hubert SM, Khan KB, Lu W, Kraushaar D, Song X, Zhang J, Gibbons D, Solis Soto LM, Wistuba II, Wu J, Heymach JV, Cheng C, Zhang J. Single cell and spatial profiling revealed molecular and immune evolution from precancers to invasive lung adenocarcinomas in genetic and carcinogen-induced mouse models. Annual Meeting American Association for Cancer Research 2023, 2023.
2. Han G, Sinjab A, Treekitkarnmongkol W, Rahal Z, Liu Y, Serrano AG, Feng J, Liang K, Khan K, Lu W, Hernandez S, Cao X, Dai E, Liu Y, Pei G, Hu J, Gomez Bolanos LI, Parra ER, Cascone T, Sepesi B, Moghaddam SJ, Scheet P1, Negrao MV, Heymach JV, Li M, Chen J, Dubinett SM, Fujimoto J, Solis LM, Wistuba II, Stevenson CS, Spira A, Wang L, Kadara H. An atlas of epithelial cell states and plasticity in lung adenocarcinoma. Annual Meeting American Association for Cancer Research 2023, 2023.
3. Tian Y, Li JR, Zhu B, Fradette J, Chen H, Li C, Cui S, Kraushaar D, Fujimoto J, Rodriguez L, Solis Soto LM, Reuben A, Wistuba II, Gibbons D, Chao C, Zhang J. Single-cell and spatial transcriptomic profiling reveal the cascade of immune events during progression and metastasis of non-small cell lung cancer. Annual Meeting American Association for Cancer Research 2023, 2023.
4. Rahal Z, Peng F, Liu Y, Ross MC, Sinjab A, Liang K, Feng J, Chukwuocha CO, Sharma M, Tang E, Abaya C, Petrosino J, Fujimoto J, Moghaddam SJ, Wang L, Hoffman KL, Kadara H. Gut microbiome dysbiosis promotes immune suppression and lung cancer development. Annual Meeting American Association for Cancer Research 2023, 2023.
5. Hernandez SDV, Lu W, Serrano AG, Arrechedera CJ, Sanchez-Espiridion B, Ozirmak N, Molina M, Kostousov L, Barnes S, Khan K, Tang X, Fujimoto J, Parra ER, Raso G, Schmidt ST, Behrens C, Heymach JV, Zhang J, Chen K, Sepesi B, Cascone T, Gibbons D, Wistuba II, Haymaker C, Solis LM. Spatial profiling of immune biomarkers in resected treatment-naïve early stage lung adenocarcinoma. Annual Meeting American Association for Cancer Research 2023, 2023.
6. Gay CM, Stewart CA, Frumovitz M, Fujimoto J, Xi Y, Wang Q, Wang R, Novegil V, Altan M, Cascone T, Dasari A, Elamin YY, Fossella FV, Glisson BS, Lu CS, Negrao MV, Skoulidis F, Vokes N, Cardnell RJ, Wistuba II, Wang J, Heymach JV, Byers LA. A phase II trial of niraparib plus dostarlimab in relapsed small cell lung cancer and other high-grade neuroendocrine carcinomas. Annual Meeting American Association for Cancer Research 2023, 2023.
7. Treekitkarnmongkol W, Han G, Rahal Z, Feng J, Sinjab A, Cascone T, Stevenson CS, Sweeney C, Edwards M, Spira A2, Fujimoto J, Moghaddam SJ, Wang L, Kadara H. Targeting IL-1B synergizes with PD-1 blockade for enhanced T and B cell immune responses and inhibition of early lung cancer development. Annual Meeting American Association for Cancer Research 2023, 2023.
8. White BS, Woo XY, Koc S, Sheridan T, Neuhauser SB, Wang S, Evrard YA, Landua JD, Mashl RJ, Davies SR, Fang B, Raso MG, Evans KW, Bailey MH, Chen Y, Xiao M, Rubinstein J, Foroughi pour A4, Lacey Elizabeth Dobrolecki AD, Fujita M, Fujimoto J, Xiao G, Fields RC, Mudd JL, Xu X, Hollingshead MG, Jiwani S, PDXNet consortium, Wallace TA, Moscow JA, Doroshow JH, Mitsiades N, Kaochar S, Pan CX, Chen MS, Carvajal-Carmona LG, Welm AL, Welm BE, Govindan R, Li S, Davies MA, Roth JA, Meric-Bernstam F, Xie Y, Herlyn M, Ding L, Lewis MT, Bolt CJ, Dean DA, Chuang JH. A pan-cancer PDX histology image repository with genomic and pathological annotations for deep learning analysis. Annual Meeting American Association for Cancer Research 2023, 2023.
9. Chen P, Rojas F, Hu X, Fujimoto J, Serrano A, Zhu B, Hong L, Bandyopadhyay R, Aminu M, Saad MB1, Salehjahromi M, Sujit SJ, Kalhor N, Pass HI, Moreira AL, Wistuba II, Gibbons DL4, Heymach JV, Solis Soto LM, Zhang J, Wu J. Pathomics reveals the molecular and immune evolution from lung preneoplasia to invasive adenocarcinoma. Annual Meeting American Association for Cancer Research 2023, 2023.
10. Chen H, Zhu B, Fujimoto J, Tian Y, Li JR, Chen P, Reuben A,Nilsson MB, Le X, Poteete A, Hubert SM, Gibbons DL, Wistuba II, Wu J, Cheng C, Heymach JV, Zhang J. Single-cell transcriptomic analysis reveals immune landscape in the malignant transformation of normal lung to lung adenocarcinoma in genetic murine models. Annual Meeting American Association for Cancer Research 2023, 2023.
11. Pei G, Wu J, Dai E, Liu Y, Han G, Hu J, Peng F, Cho KS, Jiang J, Zhang D, Sinjab AF, Zhang B, Song S, Fujimoto J, Solis Soto LM, Maitra A, Ajani J, Li M, Kadara H, Wang L. Pan-cancer characterization of tumor-immune interactions using spatially resolved transcriptomics. Annual Meeting American Association for Cancer Research 2023, 2023.
12. Rojas Alvarez FR, Chen P, Serrano AG, Fujimoto J, Hong L, Zhu B, Hu X, Salehjahromi M, Bandyopadhyay R, Aminu M, Kalhor N, Wistuba II, Zhang J, Wu J,Solis Soto LM. Artificial Intelligence-Assisted Tissue Morphology Analysis Reveals the Lymphocytes Infiltration Progression from Lung Preneoplasia to Invasive Adenocarcinoma. 2023 United States & Canadian Academy of Pathology annual meeting, 2023.
13. Han G, Sinjab A, Treekitkarnmongkol W, Hao D, Dai E, Solis LM, Parra ER, Swisher S, Cascone T, Sepesi B, Chen J, Dubinett S, Fujimoto J, Wistuba II Stevenson CS, Spira AE, Wang L, Kadara H. Single-cell sequencing of early-stage lung adenocarcinomas reveals prominent intratumoral heterogeneity and epithelial plasticity programs. Cancer Res. Proceedings: AACR Annual Meeting 2022 82(12):Supplement 2126, 2022.
14. Rahal Z, Hassane M, Karaoghlanian N, Zhang J, Sinjab A, Lee JJ, Raso MG, Fujimoto J, Chami H, Shihadeh A, Kadara H. Chronic exposure to waterpipe smoke elicits immunomodulatory and carcinogenic effects in the lung. Cancer Res. Proceedings: AACR Annual Meeting 2022 82(12):Supplement Abstract 223, 2022.
15. White BS, Woo X, Koc S, Sheridan T, Neuhauser SB, Savaliya AM, Dobrolecki LE, Landua JD, Bailey MH, Fujita M, Evans KW, Fang B, Fujimoto J, Raso MG, Wang S, Xiao G, Xie Y, Davies SR, Fields RC, Mashl RJ, Mudd JL, Chen Y, Xiao M, Xu X, Hollingshead MG, Jiwani S; PDXNet Consortium, Evrard YA, Wallace TA, Moscow JA, Doroshow JH, Mitsiades N, Kaochar S, Pan C, ChenMS, Carvajal-Carmona LG, Welm AL, Welm BE, Lewis MT, Govindan R, Ding L, Li S, Herlyn M, Davies MA, Roth JA, Meric-Bernstam F; Bult CJ, Davis-Dusenbery B, Dean DA, Chuang JH. A repository of PDX histology images for exploring spatial heterogeneity and cancer dynamics. Cancer Res. Proceedings: AACR Annual Meeting 2022 82(12):Supplement Abstract 1202, 2022.
16. Lima CF, Rocha PS, Fujimoto J, Stewart A, Cardnell R, Lu Wei, Khan K, Sable B, Ellison AR, Wistuba II, Gay CM, Kalhor N, Byers LA, Solis LM. Delta-like ligand 3 immunohistochemical expression landscape in high-grade lung neuroendocrine tumors. Cancer Res. Proceedings: AACR Annual Meeting 2022 82(12):Supplement Abstract 5305, 2022.
17. Sinjab A, Han G, Treekitkarnmongkol W, Hao D, Dai E, LuSolis LM, Moghaddam SJ, Fujimoto J, Chen J, Edwards M, Stevenson CS, Spira AE, Wang L, Kadara H. An emerging role for inflammation-associated alveolar intermediate cells in early phenotypic development of KRAS-mutant lung adenocarcinom. Cancer Res. AACR Special Conference: Evolutionary Dynamics in Carcinogenesis and Response to Therapy 82(10):Supplement, 2022.
18. Schmidt ST, Akhave N, Knightly RE, Reuben A, Vokes N, Zhang J, Li J, Fujimoto J, Byers LA, Sanchez-Espiridion B, Diao L, Wang J, Federico L, Forget MA, McGrail DJ, Weissferdt A, Lin SY, Lee Y, Suzuki E, Kovacs JJ, Behrens C, Wistuba II, Futreal A, Vaporciyan A, Sepesi B, Heymach JV, Bernatchez C, Haymaker C, Cascone T, Zhang J, Bristow CA, Heffernan TP, Negrao MV, Gibbons DL; ICON Team. A shared nearest neighbors approach for integrated, multi-platform networks and its application to the exploration of multiomics data from early-stage non-small cell lung cancers. Mol Cancer Ther AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics 20(12_Supplement):P009, 2021.
19. Cai L, Liu H, Huang F, Fujimoto J, Girard L, Xie Y, Minna J, Gazdar A. Relationship between neuroendocrine and immune gene expression in small cell lung cancer. Annual Meeting American Association for Cancer Research 2021, 2021.
20. Zhang B,  Stewart CA, Gay CM, Wang Q, Cardnell R, Fujimoto J, Fernandez L, Jendrisak A, Gilbertson C, Schonhoft J, Jones J, Anderson AKL, Wistuba II, Wang J, Wenstrup R, Byers LA.. Detection of DNA replication blocker SLFN11 in tumor tissue and circulating tumor cells to predict platinum response in small cell lung cancer. Annual Meeting American Association for Cancer Research 2021, 2021.
21. Akhave N, Schmidt S, Reuben A, Cascone T, Zhang J, Li J, Fujimoto J, Byers LA, Sanchez-Espiridion B, Diao L, Wang J, Federico L, Forget MA, McGrail DJ, Weissferdt A, Lin SY, Lee Y, Behrens C, Wistuba II, Futreal PA, Vaporciyan A, Sepesi B, Heymach JV, Bernatchez C, Haymaker C, Zhang J, Bristow CA, Negrao MV, Gibbons DL. Integrated multi-platform profiling of early-stage non-small cell lung cancer identifies relationship between disease recurrence and decreased native immune response in treatment-naïve resected NSCLC. Annual Meeting American Association for Cancer Research 2021, 2021.
22. Han G, Sinjab A, Hara K, Treekitkarnmongkol W, Brennan P, Chang K, Bokatenkova E, Sanchez-Espiridion B, Behrens C, Solis LM, Gao B, Girard L, Zhang J, Sepesi B, Cascone T, Byers LA, Gibbons DL, Chen J, Moghaddam SJ, Ostrin EJ, Scheet PA, Fujimoto J, Shay J, Heymach JV, Minna JD, Dubinett S, Wistuba II, Stevenson CS, Spira AE, Wang L, Kadara H. Single-cell expression landscape of SARS-CoV-2 receptor ACE2 and host proteases in human lung adenocarcinoma. Annual Meeting American Association for Cancer Research 2021, 2021.
23. Gay CM, Stewart CA, Diao L, Nabet BY, Fujimoto J, Solis LM, Lu W, Xi Y, Cardnell RJ, Vokes NI, Ramkumar K, Swisher SG, Roth JA, Glisson BG, Shames DS, Wistuba II, Wang J, Minna JD, Heymach JV, Byers LA. A novel, inflamed small cell lung cancer transcriptional subtype, SCLC-I, defines a subset of patients with distinct immunotherapy vulnerability. Annual Meeting American Association for Cancer Research 2021, 2021.
24. Sinjab A, Han G, Treekitkarnmongkol W, Hara K, Brennan P, Dang M, Hao D, Wang R, Dai E, Dejima H, Zhang J, Bogatenkova E, Sanchez-Espiridion B, Chang K, Little DR, Bazzi S, Tran L, Krysan K, Behrens C, Duose D, Parra ER, Raso MG, Solis LM, Fukuoka J, Zhang J, Sepesi B, Cascone T, Byers LA, Gibbons DL, Chen J, Moghaddam SJ, Ostrin EO, DG, Heymach JV, Scheet PA, Dubinett S, Wistuba II, Fujimoto J, Stevenson CS, Spira AE, Wang L, Kadara H. Resolving the spatial and cellular architecture of lung adenocarcinoma by multi-region single-cell sequencing. Annual Meeting American Association for Cancer Research 2021, 2021.
25. Dacic S, Travis WD, Giltnane J, Abel J, Kos F, Hilz S, Hennek S, Fujimoto F, Sholl L, Khalil F, Ritter J, D’Apuzzo M, Lee JM, Rusch V, Carbone D, Nicholas A, Johnson A, Schulze K, Kris MG, Wistuba II. Artificial intelligence (AI)–powered pathologic response (PathR) assessment of resection specimens after neoadjuvant atezolizumab in patients with lung cancer: results from the LCMC3 study. 2021 ASCO Annual Meeting, 2021.
26. Sinjab A, Han G, Treekitkarnmongkol W, Brennan P, Hara-Kobayashi K, Chang K, Bogatenkova E, Sanchez-Espiridion B, Behrens C, Zhang J, Sepesi B, Cascone T, Gibbons DL, Chen J, Eapen G, Ostrin EJ, Fujimoto J, Scheet P, Wistuba II, Wang L, Kadara H. A Single-Cell Transcriptomic Atlas of Lung Adenocarcinoma and Adjacent Normal-Appearing Tissue. Annual Meeting American Association for Cancer Research 2020, 2020.
27. Stewart CA,  Gay CM, Xi Y, Sivajothi S, Fujimoto J, Hartsfield PM, Tran H, Stephen G. Swisher SG, Roth JA, Zhang J, Glisson B, Heymach JV, Wistuba II, Robson P, Wang J, Byers LA. Paired, single-cell profiling of circulating tumor cell-derived xenograft models of small cell lung cancer reveals intratumoral heterogeneity and emergence of new cell clusters following treatment relapse. Annual Meeting American Association for Cancer Research 2020, 2020.
28. Treekitkarnmongkol W, Finnicum C, Sinjab A, Hassane M, Davis C, Davies GE,  Hoffman KL, Fujimoto F,  McAllister F, Boris Sepesi, Tina Cascone, Robert R. Jenq, Joseph Petrosino, Erik Ehli, Moghaddam SJ, Kadara H . Evolution of the gut microbiome during the pathogenesis of smoking-associated Kras-mutant lung cancer. Annual Meeting American Association for Cancer Research 2020, 2020.
29. Segura RNL, Andre Catao A, SolisLM, Jiang M,  Tamegnon A,  Fujimoto J, Rodriguez-Canales J, Chow C-WB, Behrens C, Kalhor N, Weissferdt A, Heymach JV, Swisher SG, Sepesi B, Lee JJ, Moran CA, Futreal PA, Zhang J, Parra ER, Wistuba II, Tetzlaff MT, Francisco-Cruz A. Tertiary Lymphoid Structures Features Associate with Outcome in Non-Small Cell Lung Carcinoma. Annual Meeting American Association for Cancer Research 2020, 2020.
30. Reuben A, Zhang J, Gittelman R, Chiou SH, Li J, Fujimoto J, Behrens C, Kheradmand F, Chow CW, Bernatchez C, Eterovic AK, Benzeno S, Vignali M, Wu X, Ye Y, Cascone T, Herbst R, Swisher S, Kadara H, Moran C, Zhang J, Scheet P, Vaporciyan A, Sepesi B, Gibbons DL, Robins H, Hwu P, Heymach JV, Sharma P, Allison J, Lee JJ, Davis M, Wistuba II, Futreal A, Zhang J. Comprehensive characterization of the T cell repertoire in non-small cell lung cancer. 2019 World Lung Conference, 2019.
31. Chen R, Jin Y, Li J, Zhang J, Fujimoto J, Lee WC, Hu X, Chen Y, Behrens C, Chow CW, Parra ER, Little LD, Gumbs C, Song X, Roarty E, Zhang J, Gibbons DL, Heymach JV, Lee JJ, William WJ, Glisson B, Wistuba II, Futreal PA, Byers L, Reuben A, Chen M, Zhang J. Genomic and T cell repertoire intratumor heterogeneity of small-cell lung cancer by multiregion exome and TCR sequencing: an association with survival. 2019 World Lung Conference, 2019.
32. Francisco-Cruz A, Parra ER, Krishnan SN, Barua S, Jiang M, Fujimoto J, Peterson CB, Das P, Chow CW, Rodriguez-Canales J, Behrens C, Kalhor N, Weissferdt A, Heymach JV, Swisher S, Sepesi B, Rao A, Lee JJ, Moran CA, Futreal A, Zhang J, Wistuba II. Impact of the spatial analysis of tumor-associated lymphocytes and tumor-associated macrophages on recurrence at early stage of non-small cell lung carcinoma. Annual Meeting American Association for Cancer Research 2019, 2019.
33. Negrao MV, Karpinets T, Jun L, Reuben A, Haymaker C, Mitchell KG, Fujimoto J, Chow CW, Parra ER, Federico L, Zhang J, Vaporciyan AA, Bernatchez C, Cascone T, Sepesi B, Wistuba, II, Heymach JV, Zhang J, Gibbons DL, ICON Team. Immunogenomic profiling identifies a subgroup of squamous cell lung cancers with immunosuppressed tumor microenvironment and correlates TGF-beta and Wnt/beta-catenin signaling as predictive of low PD-L1 expression. Annual Meeting American Association for Cancer Research 2019, 2019.
34. Hassane M, Treekitkarnmongkol W, McDowell TL, Sivakumar S, Lang W, Ochieng JK, Nunomura-Nakamura S, Finnicum C, Davis C, Davies GE, Fukuoka J, Cascone T, McAllister F, Wistuba II, Ehli E, Moghaddam SJ, Scheet P, Fujimoto J, Kadara H. Host lipocalin 2 protects against Kras mutant lung cancer development by maintaining an anti-tumor immune contexture. Annual Meeting American Association for Cancer Research 2019, 2019.
35. Lee WC, Gomez D, Zhang J, Reuben A, Jalali A, Roh W, Wu CC, Lu W, Chow CW, Fujimoto J, Antonoff M, Moran CA, Sulman E, Rao G, Swisher S, Heymach JV, Wistuba II, Futreal A, Zhang J. Comprehensive molecular profiling of primary tumors and paired distant metastases in non-small cell lung cancer. Annual Meeting American Association for Cancer Research 2019, 2019.
36. Xu XM, Kalhor N, Fujimoto J, Weisferdt A, Solis LM, Wistuba II, Moran CA. P16 FISH and BAP1 Immunohistochemistry in Sarcomatoid Mesotheliomas. 2019 United States & Canadian Academy of Pathology annual meeting, 2019.
37. Xu XM, Kalhor N, Fujimoto J, Weisferdt A, Mino B, Wistuba II, Moran CA. Ki67, p21 and MET as Prognostic Markers in Mediastinal Neuroendocrine Carcinomas. 2019 United States & Canadian Academy of Pathology annual meeting, 2019.
38. Mitchell KG, Parra ER, Nelson DB, Corsini EM, Zhang J, Vaporciyan AA, Hofstetter W, Mehran RJ, Swisher SG, Rice DC, Sepesi B, Walsh GL, Behrens C, Kalhor N, Weissferdt A, Moran CA, Skoulidis S, Wistuba II, Fujimoto J, Roth JA, Antonoff MB. Intratumoral LKB1/STK11 Expression Correlates with Immune Cell Infiltration and Oncologic Outcomes Following Resection of Lung Adenocarcinoma. 55th The Society of Thoracic Surgeons (STS) Annual Meeting, 2019.
39. Nelson DB, Mitchell KG, Wang J, Fujimoto J, Behrans C Zheng X, Zhang J, Sepesi B, Vaporciyan AA, Hofstetter WL, Mehran RJ, Rice DC, Walsh GL, Swisher SG, Moran CA, Kalhor N, Weissferdt A, Wistuba II, Roth JA, Antonoff MB. Immune Regulatory Markers of Lepidic-Pattern Adenocarcinomas Presenting as Ground Glass Opacities. 55th The Society of Thoracic Surgeons (STS) Annual Meeting, 2019.
40. Mitchell DG, Nelson DB, Vaporciyan AA, Hofstetter WL, Mehran RJ, Swisher SG, Rice DC, Sepesi B, Walsh GL, Behrens C, Wistuba II, Fujimoto J, Roth JA, Antonoff MB. Tumor Cellular Proliferation Correlates with Immune Checkpoint Expression and Lymphocyte Infiltration in Resected Non-Small Cell Lung Cancer (NSCLC). American Association for Thoracic Surgery (AATS) International Thoracic Surgical Oncology Summit, 2018.
41. Hu X, Fujimoto J, Chen R, Chow CW, Sun W, Song X, Mao X, Scheet PA, Kadara H, Behrens C, Wu CJ, Lee JJ, Antonoff M, Vaporciyan AA, Swisher S, Zhang J, Heymach JV, Wistuba II, Futreal A, Zhang J. Genomic evolutions in the progression from lung preneoplasia to adenocarcinoma. 2018 ASCO Annual Meeting, 2018.
42. Sivakumar S, Jakubek Y, San Lucas FA, Lang W, McDowell T, Weber Z, Behrens C, Kalhor N, Moran C, El-Zein R, Davies G, Fujimoto J, Mehran R, Swisher SG, Wang J, Fowler J, Dubinett S, Spira AE, Ehli E,Wistuba II, Scheet P, Kadara H. Somatic mutational processes in the cancerization field of the normal-appearing airway reveal early drivers in the development of non-small cell lung cancer. Annual Meeting American Association for Cancer Research 2018, 2018.
43. Stewart CA, Gay CM, Xi Y, Siva V, Fujimoto J, Tong P, Diao L, Li L, Bolisetty M, Kalhor N, Lawson P, Vasquez M, Tran H, Wistuba II, Glisson B, Heymach JV, Robson P, Wang J, Byers LA. Single-cell profiling of small cell lung cancer circulating tumor cell-derived xenograft models reveals intratumoral heterogeneity among putative mediators of chemoresistance. Annual Meeting American Association for Cancer Research 2018, 2018.
44. Chen R, Fujimoto J, Reuben A, Ying L, Hu X, Chow C-W, Canales J, Sun W, Hu J, Parra Cuentas E, C. Behrens C, Wu C-J, Little L, Gumbs C, Wiesnoski D, Han G, Lee W-C, Scheet P, Kadara H, Antonoff M, Vaporciyan AA, Swisher S, Zhang J, Heymach JV, Hong WK, Wistuba II, Futreal1 A, Su D, Zhang J. T cell repertoire evolution from the normal lung to invasive lung adenocarcinoma. Annual Meeting American Association for Cancer Research 2018, 2018.
45. Khalil A, Fujimoto J, McDowell C, Scheet P, Nemer G, Kadara H. Early suppression of the TBX2 subfamily of transcription factors during in vivo tobacco carcinogen-mediated lung adenocarcinoma development. Annual Meeting American Association for Cancer Research 2018, 2018.
46. Hu X, Fujimoto J, Ying L, Chen R, Estecio M, Chow C-W, Canales J, Song X, Mao X, Scheet P, Kadara H, Cuentas E, Behrens C, Wu C-J, Lee JJ, Antonoff M, Vaporciyan A, Swisher SG, Zhang J, Heymach JV, Hong WK, Wistuba II, Sun W, Hu J, Futreal P, Su D, Zhang J. Tracking genomic and epigenomic evolution from preneoplastic lesions to lung adenocarcinoma by multiregion sequencing. Annual Meeting American Association for Cancer Research 2018, 2018.
47. Hillman RT, Cardnell R, Fujimoto J, Byers LA, Futreal PA, Frumovitz M. Genomic landscape of small cell neuroendocrine cervical cancer. 2018 the Society of Gynecologic Oncology (SGO) Annual Winter Meeting, 2018. e-Pub 2017.
48. Federico L, Haymaker C, Forget MA, Ravelli A, Bhatta A, Karpinets T, Zang R, ICON team, Fang B, Zhang J, Wagner H, Bogatenkova E, Wistuba II, Sepesi B, Heymach J, Gibbons D, Bernatchez C ICON Team: Weissferdt A, Vaporciyan A, Futreal A, Zhang J, Lizee G, Talukder A, Roszik J, Tran H, Behrens C, Parra E, Rodriguez-Canales J, Fujimoto J, Allison J, Sharma P, Vence L, Roth J, Meraz I, Roarty E, Lacerda L, Byers L, Swisher S, William WN Jr. A preclinical study on the feasibility of adoptive cell transfer (ACT) of autologous tumor-infiltrating lymphocytes as a T cell-based immunotherapy treatment for NSCLC. 2018 ASCO-SITC Clinical Immuno-Oncology Symposium, 2018.
49. Francisco-Cruz A, Parra ER, Fujimoto J,Chow CW, Rodriguez-Canales J, Behrens C, Kalhor N, Weissferdt A, Heymach JV, Swisher S, Sepesi B, Lee JJ, Moran C, Futreal PA, Zhang J, Wistuba II. Intra-tumor heterogeneity analysis of immune response in early stage of non-small cell lung carcinoma using multiplex immunofluorescence and image analysis approaches: methodology and preliminary results. 2017 Innovations In Cancer Prevention and Research Conference, 2017.
50. Wang Y, Gudikote J, Yan J, Deng W, Jiang W, Hobbs BP, Wang J, Swisher SG, Fujimoto J, Wistuba II, Komaki R, Heymach JV, Lin SH. RAD50 expression is associated with poor clinical outcomes after radiotherapy in resected non-small cell lung cancer. Int J Radiat Oncol Biol Phys 99(2):S200. e-Pub 2017.
51. Zhang J, Su D, Fujimoto J, Ying L, Chow CW, Sun W, Zhang J, Hu J, Behrens C, Little L, Gumbs C, Antonoff M, Vaporciyan A, Swisher SG, Lee JJ, Heymach JV, Hong WK, Wistuba II, Futreal PA. Multiregion whole exome seuquencing of precursors of invasive lung adenocarcinomas. J Clin Oncol 35(suppl; abstr e20077), 2017.
52. Quek K, Jun Li J, Fujimoto J, Zhang J, Wang J, Chow CW, Behrens C, Early NSCLC ITH group, Little L, Gumbs C, Antonoff M, Kalhor N, Weissferdt A, William WN Jr, Swisher SG, Lee JJ, Heymach JV, Wistuba II, Futreal PA, Zhang J. Intratumor heterogeneity of stage IA lung adenocarcinoma by multiregion whole exome sequencing: an association with survival. J Clin Oncol 35(suppl; abstr 8545), 2017.
53. Tang M, Kalhor N, Ramineni M, Fujimoto J, Zhang J, Li J, Chow CW, Mao X, Song X, Little L, Gumbs C, Behrens C, Moran CA, Weissferdt A, Lee JJ, Swisher SG, Heymach JV, Wistuba II, Futreal PA, Zhang J. Histology determination of lung cancers: a report on genomic profiling of lung cancer of mixing histology. J Clin Oncol 35(suppl; abstr 8570), 2017.
54. Reuben A, Gittelman R, Zhang J, Yusko E, Wu CJ, Emerson RO, Zhang J, Tipton C, Vignali M, Fujimoto J, Rodriguez-Canales J, Swisher SG, Heymach JV, Robins H, Lee JJ, Futreal PA, Wistuba II, Zhang J, NSCLC TCR Study Team. TCR repertoire sequencing of 254 resected non-small cell lung cancers reveals higher TCR clonality in normal tissues than tumor tissues. J Clin Oncol 35(suppl; abstr 11500), 2017.
55. Seth S, Lee WC, Zhang J, Fujimoto J, Behrens C, McDowell C, Kalhor N, Weissferdt A, Papadimitrakopoulou V, Heymach JV, Gibbons DL, Futreal PA, Wistuba II, Amit M, Kadara H, Zhang J. Genomic and transcriptomic profiling of localized sarcomatoid carcinoma of the lung reveals association between immune activation and a lower risk of recurrence. J Clin Oncol 35(suppl; abstr e20058), 2017.
56. Sivakumar S, Jakubek Y, Lang W, McDowell C, Garcia MM,Chow CW, Weber Z, Behrens C, Kalhor N, Moran CA, El-Zein R, Davies G, Fujimoto J, Mehran R, Swisher SG, Wang J, Spira AE, Fowler J, San Lucas FA, Wistuba II, Ehli E, Scheet P, Kadara H. Mutational landscape in the normal-appearing airway cancerization field of early-stage non-small cell lung cancer. Annual Meeting American Association for Cancer Research 2017, 2017. e-Pub 2017.
57. Byers LA, Krug LM, Waqar SN, Dowlati A, Hann CL, Chiappori A, Owonikoko TK, Woo KM, Bensman Y, Hurtado B, Cardnell R, Diao L, Fan Y, Fujimoto J, Rodriguez-Canales J, Long L, Sulman EP, Wistuba II, Wang J, Travis WD, Chen AP, Rudin C, Kris MG, Fleisher M, Heymach J, Pietanza MC. Improved small cell lung cancer (SCLC) response rates with veliparib and temozolomide: Results from a phase II trial. 2016 World Lung Conference, 2016.
58. Dodge M, Filipovic-Sadic S , Chen L, Fujimoto J, Papadimitrakopoulou VA, Wistuba II, Latham GJ. A novel RT-ddPCR assay enables sensitive and accurate quantification of MET exon 14 skipping in lung adenocarcinomas. The Association for Molecular Pathology (AMP) 2016 annual meeting, 2016.
59. Haynes BC, Blidner R, Krosting J, Gokul S, Dodge M, Zeigler R, Chen L, Fujimoto J, Kahlor N, Papadimitrakopoulou VA, Wistuba II, Latham GJ. A Modular Next-generation Sequencing Technology that Combines Targeted Enrichment and Bioinformatics Analyses to Reveal RNA Expression and DNA Mutations in Lung Cancer. The Association for Molecular Pathology (AMP) 2016 annual meeting, 2016.
60. Scheet P, Sivakumar S, McDowell CL, Jakubek YA, Lang W, Xu L, Chow C, Wang J, Fujimoto J, Fowler J, Davies GE, Wistuba II, Ehli E, Kadara H. Landscape of somatic mutations in the normal-appearing airway cancerization field of early-stage non-small cell lung cancer. The American Society of Human Genetics Annual Meeting 2016, 2016.
61. Haynes BC, Blidner R, Krosting J, Gokul S, Dodge M, Zeigler R, Chen L, Fujimoto J, Kahlor N, Papadimitrakopoulou VA, Wistuba II, Latham GJ. QuantideX Targeted RNA-Seq Enables Sensitive and Accurate Detection of Gene Fusions, MET Exon 14 skipping and Expression Profiling of FFPE Lung Cancer Specimens. Advances in Genome Biology and Technology (AGBT) Precision Health Meeting 2016, 2016.
62. Rimm DL, Han G, Taube JM, Yi ES, Bridge JA, Flieder DB, Homer R, West WW, Wu H, Roden AC, Fujimoto J, Yu H, Anders R, Kowalewski A, Rivard C, Rehman J, Hirsch FR, Wistuba II. A Prospective, Multi-Institutional Assessment of Four Assays for PD-L1 Expression in NSCLC by Immunohistochemistry. The International Association for the Study of Lung Cancer (IASLC) Multidisciplinary Symposium in Thoracic Oncology in Chicago 11(11,Supplement):S249, 2016. PMID: 27969440.
63. Pietanza MC, Krug LM, Waqar SN, Dowlati A, Hann CL, Chiappori A, Owonikoko TK, Woo K, Bensman Y, Hurtado B, Fujimoto J, Wistuba II, Travis WD, Chen AP, Heymach J, Kris MG, Fleisher M, Rudin CM, Byers LA. A Multi-Center, Randomized, Double-Blind Phase II Study Comparing Veliparib (ABT-888), a PARP Inhibitor, versus Placebo with Temozolomide (TMZ) in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer (SCLC). 2016 ASCO Annual Meeting, 2016.
64. Zhang J, Fujimoto J, Yusko EC, Zhang, J Vignali M, Song X, Rodriguez JC, Parra Cuentas ER, Behrens C, Benzeno S, Robins H, Gibbons DL, Swisher S, Heymach JV, Futreal A, Wistuba II. Intra-tumor heterogeneity of T cell receptor repertoire in lung adenocarcinomas and its association with tumor genomic profile. 2016 ASCO Annual Meeting, 2016.
65. Latham GJ, Krosting J, Dodge M, Zeigler R, Chen L, Plyler J, Gokul S, Fujimoto J, Papadimitrakopoulou VA, Wistuba II, Blidner R, Haynes BC. A Unified and Streamlined Targeted Sequencing System for the Quantification of DNA Mutations and RNA Expression Markers in Lung Cancer. Annual Meeting American Association for Cancer Research, 2016, 2016.
66. Kadara H, Choi M, Zhang J, Cuentas EP, Canales JR, Gaffney SG, Zhao ZM, Behrens C, Fujimoto J, Chow CW, Kalhor N, Moran C, Rimm D, Stephen Swisher S, Gibbons D, Heymach JV, Kaftan E, Townsend JP, Lynch TJ, Schlessinger J, Lee JJ, Lifton RP, Wistuba II, Herbst RS. Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma. Annual Meeting American Association for Cancer Research, 2016, 2016.
67. Choi M, Kadara H, Zhang J, Cuentas EP, Canales JR, Gaffney SG, Zhao ZM, Behrens C, Fujimoto J, Chow CW, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons D, Heymach JV, Kaftan E, Townsend J, Lynch TJ, Schlessinger J, Lee JJ, Lifton RP, Herbst RS, Wistuba II. Mutation and immune profiles in early-stage lung squamous cell carcinoma. Annual Meeting American Association for Cancer Research, 2016, 2016.
68. Fujimoto J, Nunomura S, Lang W, Liu Y, Wei J, Ochieng J, Jakubek Y, Ostrin E, Petersen J, Davies G, Darwiche N, Ehli E, Fowler J, Scheet P, Kadara H. Development of Kras mutant lung adenocarcinoma in tobacco carcinogen exposed mice with knockout of the airway lineage-specific G-protein coupled receptor Gprc5a. Annual Meeting American Association for Cancer Research, 2016, 2016.
69. Ochieng J, Nunomura S, Lang W, Wei J, Xu L, McDowell C, Ostrin E, Arlinghaus R, Fujimoto J, Kadara H. Expression of the lipocalin 2 oncogene in the development of smoking-associated and Kras mutant lung adenocarcinoma. Annual Meeting American Association for Cancer Research, 2016, 2016.
70. Lin SH, Mansfield JR, Rao X, Jiang W, Fang P, Roman K, Wang C, Komaki R, Hahn S, Swisher SG, Fujimoto J, Wistuba II, Wang J, Hoyt CC. Multiplex in situ Immunoprofiling and Survival Outcomes in Non-Small Cell Lung Cancer. Annual Meeting American Association for Cancer Research, 2016, 2016.
71. Zhang J, Wu CC, Zhang J, Fujimoto J, Song X, Mao X, Sun H, Seth S, Thornton R, Coyle M, Little L, Gumbs C, Behrens C, Chow CW, Sulman E, Rao G, Swisher S, Wistuba I, Heymach J, Futreal A, Gomez D.. Integrated exome and transcriptome sequencing of primary lung cancers and paired distant metastases. Annual Meeting American Association for Cancer Research, 2016, 2016.
72. Pozo K, Zahler S, Oltmann SC, Nwariaku FE, Grubbs EG, Fujimoto J, Takahashi M, Bibb JA. Characterization of the mode of action of Vandetanib in a mouse model for medullary thyroid carcinoma. The American Association of Endocrine Surgeons 37th Annual Meeting, 2016.
73. Latham GJ, Zeigler R, Plyler JR, Sah S, Chen L, Zhu H, Hadd AG, Fujimoto J, Papadimitrakopoulou VA, Wistuba II, Blidner R, Haynes BC. An Integrated System for Targeted Next-Generation Sequencing that Analyzes DNA Mutations, RNA Fusions and Gene Expression in Cancer. The 2015 CPRIT Innovations in Cancer Prevention and Research, 2015.
74. Scheet P, Jakubek Y, Lang W, Vattathil S, Garcia M, Huang L, Weber Z, Davies G, Behrens C, Kalhor N, Moran C, Fujimoto J, Mehran R, Fowler J, Ehli EA, Wistuba II. The genomic landscape of allelic imbalance in the normal-appearing airway field of cancerization. The 2015 CPRIT Innovations in Cancer Prevention and Research, 2015.
75. Haynes BC, Blidner R, Zeigler R, Plyler J, Sah S, Chen L, Zhu H, Hadd A, Fujimoto J, Papadimitrakopoulou VA, Wistuba II, Latham GJ. An Integrated System for Targeted Next-Generation Sequencing that Enables Simultaneous Analysis of DNA Mutations, RNA Fusions and Gene Expression in Residual Clinical FFPE, FNA, and Liquid Biopsies. AMP 2015 Annual Meeting, 2015.
76. Zhang J, Liu Y, Zhang J, Gomez DR, Fujimoto J, Behrens C, Zhang J, Correa AM, Gumbs C, Mao X, Seth S, Song X, Heymach J, Lee JJ, Swisher S, William Jr. WN, Hong WK, Gao Y, Wistuba II, Futreal A. Genomic heterogeneity of lung cancers and its potential clinical implications. 2015 ASCO Annual Meeting, 2015.
77. Jakubek Y, Lang W, Vattathil S, Garcia M, Huang L, Lu W, Chow C, Weber Z, Davies GE, Behrens C, Kalhor N, Moran CA, Fujimoto J, Fowler J, Ehli EA, Wistuba II, Scheet P, Kadara H. The genomic landscape of allelic imbalance in the normal-appearing airway field of cancerization. Annual Meeting American Association for Cancer Research, 2015, 2015.
78. Weissferdt A, Kalhor N, Fujimoto J, Rodriguez J, Mino B, Nunomura S, Parra E, Wistuba II, Moran CA. Expression of PD1 and its ligand PD-L1 in thymic epithelial neoplasms: an immunohistochemical study of 100 cases. 104th United States & Canadian Academy of Pathology annual meeting 28(Supplement 2), 2015.
79. Weissferdt A, Kalhor N, Liu H, Rodriguez J, Fujimoto J, Wistuba II, Moran CA. PULMONARY SPINDLE CELL CARCINOMAS: A CLINICOPATHOLOGICAL AND IMMUNOHISTOCHEMICAL STUDY OF 40 CASES. 104th United States & Canadian Academy of Pathology annual meeting 28(Supplement 2), 2015.
80. Parra E, Mino B, Fujimoto J, Tang X, Kalhor N, Weissferdt A, Moran CA, Behrens C, Wistuba II, Rodriguez J. Use of Histology Pattern Recognition Software for PD-L1 Immunoprofiling of Lung Cancer. 104th United States & Canadian Academy of Pathology annual meeting 28(Supplement 2), 2015.
81. Parra E, Mino B, Riquelme E, Tang X, Fujimoto J, Liu H, Blando J, Rodriguez J. Validation of PD-L1 antibodies for Immunohistochemistry (IHC) on Formalin Fixed, Paraffin Embedded (FFPE) Human Tissues. 104th United States & Canadian Academy of Pathology annual meeting 28(Supplement 2), 2015.
82. Lin SH, Gudikote J, Giri U, Fujimoto J, Wang J, Wei C, Chen H, Farnia B, Gomez DR, Story MD, Komaki RU, Swisher SG, Wistuba II, Heymach JV. RAD50 Expression Predicts for Locoregional Failure and Distant Metastatic Recurrence After Postoperative Radiation Therapy in Resected Non-Small Cell Lung Cancer. International Journal of Radiation Oncology, Biology, Physics 90(5):S77-S78, 2014.
83. Aisner D, Sholl LM, Varella-Garcia M, Berry LD, Dias-Santagata D, Wistuba II, Heidi Chen H, Fujimoto J, Kugler K, Franklin WA, Johnson BE, Minna JD, Kris MG, Bunn PA, Kwiatkowski DJ. Multi-institutional multiplexed genetic analysis in lung adenocarcinoma: The Lung Cancer Mutation Consortium (LCMC I) experience. 2014 ASCO Annual Meeting. e-Pub 2014.
84. Zhang J, Fujimoto J, Zhang J, Cao Y, Chow C, Gold KA, Gumbs C, Heymach J, Kalhor N, Moran C, Protopopov A, Seth S, Song X, Swisher S, Tang J, William WN, Wu X, Hong WK, Wistuba II, Futreal A. Intratumor heterogeneity (ITH) of lung adenocarcinomas defined by multiregion whole exome sequencing (WES). 2014 ASCO Annual Meeting. e-Pub 2014.
85. Maki Y, Fujimoto J, Yoo SY, Garcia MM, Chow CW, Chu Z, Shen L, Kalhor N, Moran CA, Wang J, Coombes KR, Wistuba II, Kadara H. The transcriptomic architecture of the field of cancerization in the adjacent normal-appearing airway comprises early mechanisms in lung carcinogenesis. Annual Meeting American Association for Cancer Research, 2014, 2014.
86. Kusko R, Anderlind C, Wang G, Zhang S, Wallace D, Walser T, Ebright M, Garcia MM, Eisenberg R, Lee G, Liu G, Elashoff D, Kalhor N, Moran C, Mehran R, Fujimoto J, Massion PP, Dubinett S, Wistuba II, Lenburg M, Kadara H, Spira A. Mapping the airway-wide molecular field of injury in smokers with lung cancer. Annual Meeting American Association for Cancer Research, 2014. e-Pub 2014.
87. Fujimoto J, Hori T, Weissferdt A, Kalhor N, Fukuoka J, Wistuba II, Moran C. Histopathological evaluation of thymic epithelial tumors using spiral array technology. The 103rd Annual Meeting of the Japanese Society of Pathology, 2014.
88. Zhang YA, Ma X, Fujimoto J, Wistuba II, Lam S, Stastny V, Gao B, Larsen J, Liu X, Minna JD, Zhang MQ, Gazdar AF. SCT methylation is a potential cancer biomarker for lung cancer. Annual Meeting American Association for Cancer Research, 2014, 2014.
89. Fujimoto J, Zhang J, Pickering CR, Kadara H, Liu CG,Drummond JA, Muzny DM, Doddapaneni HV, Weissferdt A, Wheeler DA, Myers JN, Wang J, Wistuba II, Kalhor N, Moran C. Identification of Novel Somatic Variants in Thymic Epithelial Tumors by Next-Generation Sequencing. 103rd United States & Canadian Academy of Pathology annual meeting, 2014.
90. Fujimoto J, Kadara H, Wistuba II. Challenges to Investigate Lung Carcinogenesis at the University of Texas M.D. Anderson Cancer Center Thoracic Molecular Pathology Lab. 18th Congress of the Asian Pacific Society of Respirology, 2013.
91. Fujimoto J, Wistuba II. Challenges Personalized Medicine at MD Anderson Cancer Center Thoracic Molecular Pathology Lab. The 51st Annual Meeting of Japan Society of Clinical Oncology, 2013.
92. Zhang YA, Ma X, Fujimoto J, Wistuba I, Lam S, Stastny V, Gao B, Larsen J, Liu X, Minna JD, Zhang MQ, Gazdar AF. SCT methylation is a highly sensitive and specific biomarker for lung cancer. the Canary Foundation Early Detection Symposium, 2013.
93. Gold KA, Byers LA, Fan YH, Fujimoto J, Tse W, Lee JJ, Gupta S, Wistuba II, Stewart DJ, Gibbons DL. A Phase I/II Trial Combining Erlotinib (E) with Gamma Secretase Inhibitor RO4929097 (R) in Advanced Non-Small Cell Lung Cancer (NSCLC). 2013 ASCO Annual Meeting, 2013.
94. Kilari D, Tang X, Chow CW, Fujimoto J, Kalhor N, Swisher S, Wistuba II, Stewart DJ, Siddik ZH, Kim ES. Copper transporter CTR1 expression and tissue platinum concentration in NSCLC. 2013 ASCO Annual Meeting, 2013.
95. Maki Y, Fujimoto J, Yoo SY, Gower A, Kabbout M, Shen L, Garcia MG, Chow CW, Hong WK, Kalhor N, Wang J, Moran CA, Spira A, Coombes KR, Wistuba II, Kadara H. Transcriptomic architecture of the airway field cancerization in early-stage non-small cell lung cancer. The 104th Annual Meeting American Association for Cancer Research, 2013, 2013.
96. Kalhor N, Fujimoto J, Rodriguez J, Byers LA, Kies MS, Hofstetter WL, El-Naggar AK, Bell D. MECT1-MAML2 Fusion Transcript Expression in Lung Mucoepidermoid Carcinoma. The 102nd USCAP Annual Meeting 2013, 2013.
97. Fujimoto J, Suraokar M, Fukuoka J, Aoe K, Kadara H, Behrens C, Hori T, Fujimoto N, Kishimoto T, Inai K, Hiroshima K, Mehran R, Tsao A, Wistuba II. The University of Texas MD Anderson Cancer Center Mesothelioma Program. The 53rd Annual Meeting of the Japan Lung Cancer Society, 2012, 2012.
98. Fukuoka J, Hori T, Fujimoto J. Make of Tissue Bank Using Various Tissue Microarray Methods. The 38th Annual National Society for Histotechnology Symposium, 2012, 2012.
99. Behrens C, Lombardi F, Wagner S, Fujimoto J, Raso MG, Spaggiari L, Galetta D, Huges E, Reid JE, Sangale Z, Swisher S, Kalhor N, Moran C, Gutin A, Lanchbury JS, Kim ES, Barberis M, Wistuba II. A proliferation-based mRNA signature predicts outcome in early stage non-small cell lung adenocarcinoma. 2012 ASCO Annual Meeting, 2012.
100. Tsao AS, Harun N, Fujimoto J, Devito V, Lee JJ, Mehran RJ, Hong WK, Suraokar MB, Wistuba II. Elevated PDGFRB gene copy number gain is prognostic in resected malignant pleural mesothelioma. 2012 ASCO Annual Meeting, 2012.
101. Galindo HG, Sollis LM, Fujimoto J, Hanson N, McDowell C, Riquelume E, Tang XM, Behrens C, Lee JJ, Kim ES, Wistuba II, Erickson H. FFPE DNA Recovery for High-throughput Genotyping of NSCLC Tissues. The 103rd Annual Meeting American Association for Cancer Research, 2012, 2012.
102. Fujimoto J, Kadara H, Fukuoka J, Aoe K, Fujimoto N, Kishimoto T, Inai K, Hiroshima K, Suraokar M, Tsao AS, Mehran R. Expression patterns of the G protein-coupled receptor, GPRC5A, in human malignant pleural mesothelioma. The 103rd Annual Meeting American Association for Cancer Research, 2012, 2012.
103. Kadara H, Fujimoto J, Woo SY, Garcia M, Kabbout M, Basey A, Wang J, Coombes KR, Kim ES, Hong WK, Kalhor N, Moran C, Wistuba II. Gene expression profiling of lung tumors and matched normal airways reveals common and disparate aberrant pathways in squamous cell carcinoma and adenocarcinoma development and potential markers for detection and targets for chemoprevention in early stage lung cancer. The 103rd Annual Meeting American Association for Cancer Research, 2012, 2012.
104. Kabbout M, Garcia M, Fujimoto J, Chow CW, Woods D, Koch P, Solis LM, Behrens C, Wistuba II, Kadara H. Tumor suppressor effects of ETS2 transcriptional factor in human non-small cell lung cancer pathogenesis. The 103rd Annual Meeting American Association for Cancer Research, 2012, 2012.
105. Fujimoto J, Kadara H, Fukuoka J, Aoe K, Fujimoto N, Kishimoto T, Inai K, Hiroshima K, Suraokar MB, Mehran RJ, Tsao AS, Wistuba II. Expression patterns of the G protein-coupled receptor, GPRC5A, in human malignant pleural mesothelioma. The 101st Annual Meeting of the Japanese Society of Pathology, 2012.
106. Fujimoto J, Kadara H, Woo SK, Melinda Garcia M, Kabbout M, Basey A, Wang J, Coombes KR, Kim ES, Hong WK, Kalhor N, Moran C, Wistuba II. Gene expression profiling of lung field cancerization reveals potential targets for chemoprevention. The 101st Annual Meeting of the Japanese Society of Pathology, 2012.
107. Galindo H, Solis LM, Hanson NE, McDowell C, Fujimoto J , Riquelme E, Tang XM, Behrens C, Lee JJ, Kim ES, Wistuba II, Erickson HS. High-throughput Mutation Analysis of Formalin Fixed Paraffin-Embedded (FFPE) Non-small Cell Lung Cancer Tissues. The 12th Annual Targeted Therapies of the Treatment of Lung Cancer, 2012, 2012.
108. Suraokar M, Zhang Y, Chow CW, Kim D, Diao L, Fujimoto J, Mehran R, Wang J, Behrens C, Coombes K, Tsao AS, Wistuba II. Investigating the potential of miR-203 as a therapeutic candidate and its role in the pathobiology of malignant pleural mesothelioma (MPM). AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer: Biology, Therapy, and Personalized Medicine, 2012.
109. Kim ES, Chow CW, Kalhor N, Fujimoto J, Swisher SG, Wistuba II, Stewart DJ, Siddik Z. Effects of Tissue Platinum Concentration on Tumor Response in Non-small Cell Lung Cancer. The 14th World Conference on Lung Cancer 6(6):S400-401, 2011.
110. Papadimitrakopoulou V, Liu S, Fujimoto J, Wistuba I, Lee JJ, Marom EM, Charnsangavej C, Fossella FV, Tran HT, Blumenschein GR, Kies M, Hong WK, Stewart DJ, Tsao A. Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer. The 14th World Conference on Lung Cancer 6(6):S1235, 2011.
111. Byers LA, Nilsson M, Fujimoto J, Santigny P, Wang J, Diao L, Peyton M, Fan Y-H, Giri U, Weber S, Duchemann B, Girard L, Coombes K, Weinstein J, Minna JD, Wistuba I, Heymach JV. Investigation of PARP1 as a novel therapeutic target in small cell lung cancer. The 14th World Conference on Lung Cancer 6(6):S1530-1531, 2011.
112. Fujimoto J, Kadara HN, Behrens C, Liu D, Lee JJ, Solis LM, Kim ES, Shalafkhane A, Wistuba II, Lotan R. Implication of GPRC5A loss in lung carcinogenesis in patients with and without chronic obstructive pulmonary disease. The102nd Annual Meeting American Association for Cancer Research, 2011 52:527, 2011.
113. Solis LM, Raso MG, Fujimoto J, Behrens C, Woods D, Mendoza G, Kalhor N, Moran CA, Wistuba II. Molecular abnormalities associated to the progression of lung adenocarcinomas with BAC features from non-invasive to invasive patterns. The 102nd Annual Meeting American Association for Cancer Research, 2011 52:340, 2011.
114. Behrens C, Ping Y, Solis LM, Saintigny P, Kadara H, Fujimoto J, Moran CA, Swisher S, Heymach JV, Wistuba II. EZH2 expression is an early event in the pathogenesis of non-small cell lung cancer (NSCLC) and correlates with tumor progression. The 102nd Annual Meeting American Association for Cancer Research, 2011 52:764-765, 2011.
115. Galindo HG, Suraokar M, Behrens C, Woods D, Kalhor N, Sldape K, Fujimoto J, Herbst R Erickson H, Wistuba II. Identification of Prostate Stem Cell Antigen (PSCA) as a Potential Marker for Lung Cancer Brain Metastasis. The 102nd Annual Meeting American Association for Cancer Research, 2011 52:1238-1239, 2011.
116. Fujimoto J, Kadara HN, Behrens C, Liu D, Lee JJ, Fukuoka J, Solis LM, Kim ES, Shalafkhane A, Wistuba II, Lotan R. The G-protein coupled receptor family C group 5 member A loss is implicated in lung carcinogenesis. The 100th Annual meeting of the Japanese Society of Pathology, 2011.
117. Fujimoto J, Wang H, Lotan D, Lotan R. In vitro and in vivo expression of GPRC5A in pancreatic cancer. The 6th International Society of Gastroenterological Carcinogenesis, 2011.
118. Kong M, Lee JJ, Fujimoto J, Lotan R. Nonparametric Methods for Evaluating Drug Activity and Synergy for Three Drug Combinations. The 33rd Annual Midwest Biopharmacetical Statistics Workshop, 2010.
119. Fujimoto J, Kadara HN, Tao Q, Men T, van Pelt C, Lotan D, Lotan R. Tobacco carcinogen-enhanced lung tumorigenesis in Gprc5a knockout mice recapitulates human lung cancer development. The 101st Annual Meeting American Association for Cancer Research, 2010 51:598, 2010.
120. Chen Y, Deng J, Fujimoto J, Kadara H, Ye X, Men T, Lotan D, Lotan R. Loss of the lung-specific tumor suppressor Gprc5a causes persistent activation of Stat3 leading to increased survival signaling in normal and malignant lung epithelial cells. The 101st Annual Meeting American Association for Cancer Research, 2010 51:1213, 2010.
121. Yuan P, Kadara H, Behrens C, Tang X, Woods D, Solis LM, Huang J, Spinola M, Dong W, Yin G, Fujimoto J, Kim E, Xie Y, Girard L, Moran C, Hong WK, Minna JD, Wistuba II. Sex determining region Y-box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung. The 101st Annual Meeting American Association for Cancer Research, 2010 51:1253, 2010.
122. Fujimoto J, Kadara HN, Tao Q, Men T, Van Pelt C, Lotan D,Lotan R. Relevance of tobacco carcinogen-enhanced lung tumorigenesis in Gprc5a-KO mice to human lung cancer. The 99th Annual meeting of the Japanese Society of Pathology, 2010.
123. Deng J, Fujimoto J, Ye X, Men TT, Lin X, Chen Y, Lotan D, Lotan R. The lung tumor suppressor GPRC5A inhibits activation of NF-kB in human non-small cell lung adenocarcinoma cells. The 100th Annual Meeting American Association for Cancer Research, 2009, 2009.
124. Kadara HN, Fujimoto J, Men TT, Lotan D, Ye X, Lee JS, Lotan R. Gene expression signatures of tumor suppressor Gprc5a loss in murine lung cells predict poor survival in human lung adenocarcinomas. The 100th Annual Meeting American Association for Cancer Research, 2009, 2009.
125. Fujimoto J, Kadara HN, Men TT, Lotan R. Enhanced tobacco carcinogen-induced lung tumorigenesis in tumor suppressor Gprc5a knockout mice and its relation to human lung cancer prognosis. The 98th Annual meeting of the Japanese Society of Pathology, 2009.
126. Fujimoto J, Men TT, Van Pelt CS, Lotan R. Loss of the lung-specific tumor suppressor Gprc5a sensitizes knockout mice to NNK-induced lung carcinogenesis. American Association for Cancer Research Special Conference in Cancer Research Mouse Models of Cancer, 2009.
127. Fujimoto J, Men TT, Van Pelt CS, Lee JJ, Gu X, Kopelovich L, Lotan R. Chemoprevention of NNK-induced lung carcinogenesis in the Gprc5a knockout mouse by budesonide. The 99th Annual Meeting American Association for Cancer Research, 2008, 2008.
128. Deng J, Ye X, Fujimoto J, Tao Q, Men TT, Van Pelt CS, Lin X, Chen Y, Lotan D, Lotan R. Evidence for the involvement of NF-{kappa}B and inflammation in the promotion of lung carcinogenesis in the Gprc5a knockout mouse model. The 99th Annual Meeting American Association for Cancer Research, 2008, 2008.
129. Fujimoto J, Men TT, Lee JJ, Newman RA, Kopelovich L, Lotan R. Effects of the synthetic retinoid fenretinide on lung carcinogenesis in Gprc5a knockout mice exposed to the tobacco carcinogen NNK. The Symposium in honor of Dr. Levin, Colorectal Cancer: Celebrating a Career in Cancer Prevention, 2007.
130. Fujimoto J, Men TT, Lee JJ, Newman RA, Kopelovich L, Lotan R. Effects of the synthetic retinoid fenretinide on lung carcinogenesis in Gprc5a knockout mice exposed to the tobacco carcinogen NNK. The 98th Annual Meeting American Association for Cancer Research, 2007, 2007.
131. Lotan R, Men TT, Fujimoto J, Ye X, Deng J, Lacroix L, Mao L, Van Pelt C, Tao Q. GPCR5A knockout mouse: A new model for lung carcinogenesis. Fifth AACR International Conference on Frontiers in Cancer Prevention Research, 2006.
132. Jun KH, Fujimoto J, Lotan R. Enhancement of apoptosis induction by the synthetic retinoid MX3350-1 in non-small cell lung cancer cells by p53-dependent pathway. The 97th Annual Meeting American Association for Cancer Research, 2006.
133. Fujimoto J, Hong WK, Lotan R. Antineoplastic action of 5-aza-2'-deoxycytidine and suberoylanilide hydroxamic acid (SAHA) on human lung carcinoma cells. The 96th Annual Meeting American Association for Cancer Research, 2005.

Book Chapters

1. Tahara E., Fujimoto J, Yasui W, Yokozaki H. Dysplasia in the stomach. In: The Proceeding of the 2nd International Congress on Gastroenterological Carcinogenesis. Monduzzi Editore: Ulm, Germany, 229-233, 1999.
2. Tahara E, Yokozaki H, Fujimoto J, Shimamoto F, Yasui W. Molecular mechanisms of gastric cancer and molecular diagnosis. In: The Proceeding of 3rd International Gastric Cancer Congress. Monduzzi Editore: Seoul, Korea, 97-102, 1999.
3. Tahara E, Yasui W, Fujimoto J, Yokozaki H. Genetic and epigenetic alterations in gastric cancer: Application to molecular diagnosis. In: The Proceeding of the 17th International Cancer Congress. Monduzzi Editore: Rio de Janeiro, Brazil, 919-923, 1998.